

10518347

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS	5	MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS	6	MAY 11	KOREAPAT updates resume
NEWS	7	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	8	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2
NEWS	9	MAY 30	The F-Term thesaurus is now available in CA/CAPLUS
NEWS	10	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	11	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	12	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	13	JUL 07	Coverage of Research Disclosure reinstated in DWPI
NEWS EXPRESS		JUNE 30	CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\*  
Due to STN maintenance on Sunday, July 9th, 2006, some databases may not be available until 04:00 (4:00 AM) Eastern Daylight Time.  
\*\*\*\*\*

\* \* \* \* \* STN Columbus \* \* \* \* \*

10518347

FILE 'HOME' ENTERED AT 13:35:36 ON 08 JUL 2006

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 13:36:05 ON 08 JUL 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 JUL 2006 HIGHEST RN 891019-54-8

DICTIONARY FILE UPDATES: 7 JUL 2006 HIGHEST RN 891019-54-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10518347.str



chain nodes :

7 8 9 10 11 12 13 14 15

ring nodes :

1 2 3 4 5 6 16 17 18 19 20 21

chain bonds :

3-7 6-12 7-8 8-9 9-10 9-11 12-13 13-14 14-15 15-16

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21

exact/norm bonds :

3-7 7-8 9-10 9-11 12-13 13-14 14-15 15-16

exact bonds :

6-12 8-9

normalized bonds :

10518347

1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21  
isolated ring systems :  
containing 1 : 16 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom  
19:Atom 20:Atom 21:Atom

Generic attributes :

15:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

Element Count :

Node 15: Limited


C,C2-4

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:37:16 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2239 TO ITERATE

89.3% PROCESSED 2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

28 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 41942 TO 47618  
PROJECTED ANSWERS: 291 TO 961

10518347

L2 28 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 13:37:21 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 43875 TO ITERATE

100.0% PROCESSED 43875 ITERATIONS

678 ANSWERS

SEARCH TIME: 00.00.01

L3 678 SEA SSS FUL L1

=> fil hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

167.38

167.59

FILE 'HCAPLUS' ENTERED AT 13:37:27 ON 08 JUL 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Jul 2006 VOL 145 ISS 3

FILE LAST UPDATED: 7 Jul 2006 (20060707/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 28 L3

=> d ed abs ibib hitstr 1-28

L4 ANSWER 1 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 ED Entered STN: 16 Mar 2006  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB The invention relates to thiazoles I, thiazolidenes, thiadiazoles II, and thiadiazolidenes, which are inhibitors of tyrosine phosphatases, particularly protein tyrosine phosphatase-1B (PTP-1B). In compds. I, R1 is H, alkyl, (un)substituted Ph, or (un)substituted benzyl; R2 is CF<sub>2</sub>PO<sub>3</sub>H<sub>2</sub>, NHC(O)CO<sub>2</sub>H, OCH<sub>2</sub>CO<sub>2</sub>H, CH=CHCO<sub>2</sub>H, CO<sub>2</sub>H, C(O)CO<sub>2</sub>H, or 3-carboxyisoxazol-5-yl; R3 is halo or carboxy; R4 is H, alkyl, or CH<sub>2</sub>C(O)NH<sub>2</sub>; R5 is H, CO<sub>2</sub>H, CO<sub>2</sub>Me, NHC(O)CO<sub>2</sub>H, alkylsulfonfyl, 3-carboxyphenyl, etc.; and R6 is H, CO<sub>2</sub>-alkyl, OCH(Ph)CO<sub>2</sub>H, 3-carboxyphenyl, or 2-carboxyphenyl. In compds. II, m is 0 or 1; R7 is H or halo; R8 is CF<sub>2</sub>PO<sub>3</sub>H<sub>2</sub>, CO<sub>2</sub>H, NHC(O)CO<sub>2</sub>H, CH=CHCO<sub>2</sub>H, CF<sub>2</sub>P(O)(OH)OCH<sub>2</sub>CO<sub>2</sub>-tert-Bu, or 3-carboxyisoxazol-5-yl; R9 is H, halo, pseudohalo, or carboxy; R10 is H, halo, CF<sub>2</sub>PO<sub>3</sub>H<sub>2</sub>, or SO<sub>2</sub>-heterocyclyl; R11 is H or halo; R12 is H or (un)substituted phenyl; and R13 is H or alkylsulfonfyl. The invention also relates to the preparation of the compds. of the invention.

pharmaceutical compns. comprising a compound of the invention and a pharmaceutically acceptable carrier, as well as to the use of the compns. for the treatment, prevention, or amelioration of one or more symptoms of diabetes, α-Bromination of Me 4-acetylbenzoate and cyclocondensation with (3,4-dichlorophenyl)thiourea gave thiazole III, which was alkylated with phosphonate IV (preparation from the corresponding 2-bromo-4-Me derivative given) and cleaved to give phosphonic acid V. The compds. of the invention are inhibitors of PTP-1B (no data).

ACCESSION NUMBER: 2006:236790 HCAPLUS  
 DOCUMENT NUMBER: 144:312092  
 TITLE: Thiazole and thiadiazole derivatives as inhibitors of tyrosine phosphatases, their preparation, pharmaceutical compositions, and use in therapy  
 INVENTOR(S): Cheruvallath, Zacharia S.; Loweth, Colin J.; Nutt, Ruth F.; Rideout, Darryl; Semple, J. Edward; Wang, Jing; Wu, Feiyue; Mylvaganam, Shankari; Zhu, Hengyi; Sun, Jianzhong  
 PATENT ASSIGNEE(S): Centgent Therapeutics, Inc., USA  
 SOURCE: PCT Int. Appl., 104 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006028970	A1	20060316	WO 2005-US31332	20050901
V:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,			

L4 ANSWER 1 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 1 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-607034P P 20040902  
 US 2004-638447P P 20041222  
 US 2005-642292P P 20050106


OTHER SOURCE(S): MARPAT 144:312092  
 IT 879445-42-8P, [2-Bromo-4-[[[(3,4-dichlorophenyl)[4-(4-(methanesulfonyl)phenyl)thiazol-2-yl]amino]methyl]phenoxy]acetic acid 879445-63-3P, 4-[2-[[[3-Bromo-4-carboxymethoxybenzyl](3,4-dichlorophenyl)amino]thiazol-4-yl]benzoic acid  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate: preparation of thiazole and thiadiazole derivs. as

tyrosine phosphatase inhibitors)  
 RN 879445-42-8 HCAPLUS  
 CN Acetic acid, [2-bromo-4-[[[(3,4-dichlorophenyl)[4-(4-(methylsulfonyl)phenyl)-2-thiazolyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 879445-63-3 HCAPLUS  
 CN Benzoic acid, 4-[2-[[[3-bromo-4-(carboxymethoxy)phenyl]methyl](3,4-dichlorophenyl)amino]-4-thiazolyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 17 Feb 2006  
 GI




AB Oxygen/nitrogen heterocyclic compds. (shown as I; variables defined below: e.g., [(2-bromo-4-[[[(3,4-dichlorophenyl)(5-phenyloxazol-2-yl)amino]methyl]phenyl]difluoromethyl]phosphonic acid (shown as II)), pharmaceutical compns., and methods for treating, preventing, or ameliorating symptoms associated with diseases such as diabetes, cancer, neurodegenerative diseases, and obesity are provided. The compds. and compns. inhibit protein tyrosine phosphatase enzymes, e.g., PTP-1B. For I: L1, L2, and L3 = a bond or (CH<sub>2</sub>)<sub>s</sub> where s = 1-3; X is CR<sub>7</sub> or N, wherein R7 is H or C1-C3 alkyl; G1 is H or (un)substituted Ph (substituents = phosphonodifluoromethyl, phosphonodifluoromethyl monomethyl ester, phosphonodifluoromethyl monomethyl ester, phosphonodifluoromethyl di-Et ester, phosphonodifluoromethyl monoacyloxyalkyl ester); G2 is H or (un)substituted C1-C3 alkyl, Ph or pyridyl; G3 is H, C1-C3 alkyl, or (un)substituted Ph or pyridyl; addnl. details are given in the claims. Although the methods of preparation are not claimed, preps. and/or characterization data for approx. 40 examples of I are included. For example, II was prepared (90 %) from the di-Et ester, which was prepared (63 %) from (3,4-dichlorophenyl)(5-phenyloxazol-2-yl)amine (preparation described) and [(2-bromo-4-bromomethylphenyl)difluoromethyl]phosphonic acid di-Et ester.

ACCESSION NUMBER: 2006:149918 HCAPLUS  
 DOCUMENT NUMBER: 144:212913  
 TITLE: Preparation of oxygen/nitrogen heterocycle-containing phosphonate and related inhibitors of tyrosine phosphatases with therapeutic uses  
 INVENTOR(S): Cheruvallath, Zacharia S.; Semple, Joseph E.; Wang, Jing; Nutt, Ruth F.; Mylvaganam, Shankari  
 PATENT ASSIGNEE(S): Centgent Therapeutics, Inc., USA  
 SOURCE: PCT Int. Appl., 97 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English


L4 ANSWER 2 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006017124	A2	20060216	WO 2005-0524130	20050708
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MA, MC, NL, PL, PT, RO, SD, SI, SK, TR, BF, BF, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, VG, GH, GM, KE, LI, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 2006135483	A1	20060622	US 2005-177539	20050708
PRIORITY APPLM. INFO.:			US 2004-587023P	P 20040709
			US 2004-634450P	P 20041208
			US 2004-638563P	P 20041222

OTHER SOURCE(S):	MARPAT 144:212913	95 1004 4500000	1500000
IT	875902-28-6P, [2-bromo-4-[[[3,4-dichlorophenyl] [5-(4-methylsulfonylphenyl)oxazol-2-yl]amino]methyl]phenoxy]acetic acid		
RL	PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)		
	(drug candidate; preparation of oxygen/nitrogen heterocycle-containing phosphonate and related inhibitors of tyrosine phosphatases with therapeutic uses)		
RN	875902-28-6	HCAPUS	
CN	Acetic acid, [2-bromo-4-[[[3,4-dichlorophenyl] [5-(4-methylsulfonyl)phenyl]-2-oxazolyl]amino]methyl]phenoxy]- (SCI) (CA INDEX NAME)		




L4	ANSWER 3 OF 25	HCAPLUS	COPYRIGHT 2006 ACS	ON STN	(Continued)
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, GM, KZ, MD, RU, TJ, TM				
	PRIORITY APPL. INFO.:	MARPAT	44-212778	JP 2004-229445	A 20040805
	OTHER SOURCE(S):				
IT	875656-71-6P	875656-72-7P	875656-73-8P		
	875656-74-9P	875656-75-0P	875656-76-1P		
	875656-77-2P	875656-79-4P	875656-80-8P		
	875656-81-8P	875656-82-9P	875656-83-0P		
	875656-84-1P	875656-85-2P	875656-86-3P		
	875656-89-6P	875656-90-9P	875656-91-0P		
	875656-92-1P	875656-94-3P	875656-96-5P		
	875656-98-7P	875657-01-5P	875657-02-6P		
	875657-03-7P	875657-04-8P	875657-05-9P		
	875657-06-0P	875657-07-1P	875657-08-2P		
	875657-09-3P	875657-10-6P	875657-11-7P		
	875657-12-8P	875657-13-9P	875657-14-0P		
	875657-15-1P	875657-16-2P	875657-17-3P		
	875657-18-4P	875657-19-5P	875657-20-8P		
	875657-21-9P	875657-22-0P	875657-23-1P		
	875657-27-5P	875657-28-6P	875657-29-7P		
	875657-30-0P	875657-31-1P	875657-32-2P		
	875657-33-3P	875657-34-4P	875657-35-5P		
	875657-36-6P	875657-37-7P	875657-38-8P		
	875657-39-9P	875657-40-2P	875657-41-3P		
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of pyrazole derivs. and other heterocyclic compds. as peroxisome proliferator-activated receptor $\alpha$ and $\gamma$ agonists)				
RN	875656-71-6	HCAPLUS			
CN	Propanoic acid, 2-[[4-[[[1-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]methyl]-(2-furanyl)methyl]amino]methyl]phenoxy]-2-methyl- (9CI)				(CA INDEX NAME)



RN 875656-72-7 HCAPLUS  
CN Propanoic acid, 2-[4-{{(2-furanyl)methyl}[[3-methyl-1-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl]methyl]amino}methyl]phenoxy]-2-

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN  
ED Entered STN: 09 Feb 2006  
GI




AB The title compounds 1 [ring A = 5-member aromatic heterocyclic ring; X, Y, Z = N, C, m = 0 - 3; n = 1 - 5; Q = (un)substituted benzene ring; R1 = (un)substituted Ph, naphthyl, 5- or 6-member aromatic ring; R2 = (un)substituted alkyl, (un)substituted carbamoyl, (un)substituted Ph, ethyl, R3, R4 = H, alkyl; R5 = H, alkyl, (un)substituted; R6 = H, OH, halo, etc.; when m = 1, the R6 substituent may be the same as or different from the R5 substituent] 2-[4-(((1-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl)methyl)furan-2-yl)methylamino]methyl]phenoxy]-2-methylpropionic acid was prepared in 2 steps from 4-chloromethyl-1-(4-chlorophenyl)-3-methyl-1H-pyrazole and 2-[4-(((furan-2-ylmethyl)amino)methyl]phenoxy]-2-methylpropionic acid Et ester. In GAI4-HPAPAR transactivation assays (PPAR  $\alpha$  comps. of this invention showed EC50 values of 0.0028  $\mu$ M to 0.08  $\mu$ M).


ACCESSION NUMBER:	2006:117042	HCAPLUS
DOCUMENT NUMBER:	144:212778	
TITLE:	Preparation of pyrazole derivatives and other heterocyclic compounds as peroxisome proliferator-activated receptor $\alpha$ and $\gamma$ agonists	
INVENTOR(S):	Kagechika, Katsuji; Yamaguchi, Mitsuhiro; Shibata, Yoshinori; Usui, Hiroyuki	
PATENT ASSIGNEE(S):	Daichi Pharmaceutical Co., Ltd., Japan	
SOURCE:	PCT Int. Appl., 186 pp.	
	CODEN: PIXXD2	
DOCUMENT TYPE:	Patent	
LANGUAGE:	Japanese	
FAMILY ACC. NUM. COUNT:	1	
PATENT INFORMATION:		

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006013939	A1	20060629	WO 2005-VP14332	20050804
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CI, CL, CN, CR, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GR, GU, HK, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MP, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SM, SY, TD, TH, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
methvl- (9CI) (CA INDEX NAME)




RN 875656-73-8 HCAPLUS  
CN Propanoic acid, 2-[4-[[2-(furanylmethyl)[3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875656-74-9 HCAPLUS  
CN Propanoic acid, 2-[4-[[[(2-furanylmethyl)[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]methyl]-2-methoxyphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

10518347

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 875656-75-0 HCAPLUS  
 CN Propanoic acid, 2-([4-([[(1-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl)methyl]amino)methyl]-2-methoxyphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875656-76-1 HCAPLUS  
 CN Propanoic acid, 2-([4-([[(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 875656-77-2 HCAPLUS  
 CN Propanoic acid, 2-([4-([[(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino)methyl]-2-methoxyphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875656-79-4 HCAPLUS  
 CN Propanoic acid, 2-([4-([[(1-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl)methyl]amino)methyl]phenoxy]-2-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CH 1  
 CRN 875656-78-3  
 CMF C26 H27 Cl N4 O3 S


L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CH 2  
 CRN 76-05-1  
 CMF C2 H F3 O2




RN 875656-80-7 HCAPLUS  
 CN Propanoic acid, 2-([4-([[(2-furanylmethyl)[(4-methyl-1-(4-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)methyl]amino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875656-81-8 HCAPLUS  
 CN Propanoic acid, 2-([4-([[(2-furanylmethyl)[(1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methyl]amino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 875656-82-9 HCAPLUS  
 CN Propanoic acid, 2-([4-([[(2-furanylmethyl)[(4-methyl-1-(4-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)methyl]amino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875656-83-0 HCAPLUS  
 CN Propanoic acid, 2-([4-([[(2-furanylmethyl)[(1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methyl]amino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875656-84-1 HCAPLUS  
CN Propanoic acid, 2-[(4-[(2-furanylmethyl)((3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl)amino)methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875656-85-2 HCAPLUS  
CN Propanoic acid, 2-[(4-[(2-furanylmethyl)((5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl)amino)methyl]-2-methoxyphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875656-86-3 HCAPLUS  
CN Propanoic acid, 2-[(4-[(2-furanylmethyl)((5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl)amino)methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875656-89-6 HCAPLUS  
CN Propanoic acid, 2-[2-methoxy-4-[[[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]([2-(trifluoromethyl)phenyl)methyl]amino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875656-90-9 HCAPLUS  
CN Propanoic acid, 2-[2-methoxy-4-[[[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]([3,3,3-trifluoropropyl)amino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875656-91-0 HCAPLUS  
CN Propanoic acid, 2-[4-[[[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]([2-furanylmethyl)amino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875656-92-1 HCAPLUS  
CN Propanoic acid, 2-[2-methoxy-4-[[[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]([3,3,3-trifluoropropyl)amino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875656-94-3 HCAPLUS  
CN Propanoic acid, 2-[4-[[[(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)methyl]([2-furanylmethyl)amino)methyl]-2-methoxyphenoxy]-2-methyl- (9CI) (CA INDEX NAME)






RN 875656-96-5 HCAPLUS  
CN Propanoic acid, 2-[(2-amino-2-oxoethyl)({5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl}amino)methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)





RN 875656-98-7 HCAPLUS  
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(methylamino)-2-oxoethyl]({5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl}amino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
triazol-4-yl)methyl}amino)methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI)  
(CA INDEX NAME)




RN 875657-04-8 HCAPLUS  
CN Propanoic acid, 2-[(2-methoxyethyl)({5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl}amino)methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875657-05-9 HCAPLUS  
CN Propanoic acid, 2-[4-[[[2-(methoxyethyl)({5-methyl-2-(4-methylphenyl)-2H-1,2,3-triazol-4-yl)methyl}amino)methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)





RN 875657-01-5 HCAPLUS  
CN Propanoic acid, 2-[(2-(dimethylamino)-2-oxoethyl)({5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl}amino)methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875657-02-6 HCAPLUS  
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(dimethylamino)-2-oxoethyl]({5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl}amino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875657-03-7 HCAPLUS  
CN Propanoic acid, 2-[4-[[[2-(methoxyethyl)({5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl}amino)methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-06-0 HCAPLUS  
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(methylamino)-2-oxoethyl]({5-methyl-2-(4-methylphenyl)-2H-1,2,3-triazol-4-yl)methyl}amino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875657-07-1 HCAPLUS  
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(methylamino)-2-oxoethyl]({5-methyl-2-(4-methylphenyl)-2H-1,2,3-triazol-4-yl)methyl}amino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


875657-08-2 HCAPLUS

CN Propanoic acid, 2-[4-[[[(3-methoxypropyl)[[5-methyl-2-(4-methylphenyl)-2H-1,2,3-triazol-4-yl]methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-09-3 HCAPLUS

CN Propanoic acid, 2-[4-[[[(3-methoxypropyl)[[5-methyl-2-(4-methylphenyl)-2H-1,2,3-triazol-4-yl]methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 875657-10-6 HCAPLUS

CN Propanoic acid, 2-[4-[[[(2-methoxyethyl)[[5-methyl-2-(3-methylphenyl)-2H-1,2,3-triazol-4-yl]methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 875657-13-9 HCAPLUS

CN Propanoic acid, 2-[4-[[[(3-methoxypropyl)[[5-methyl-2-(3-methylphenyl)-2H-1,2,3-triazol-4-yl]methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-14-0 HCAPLUS



CN Propanoic acid, 2-[4-[[[(3-methoxypropyl)[[5-methyl-2-(3-methylphenyl)-2H-1,2,3-triazol-4-yl]methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-15-1 HCAPLUS



CN Propanoic acid, 2-[4-[[[(3-methoxypropyl)[[5-methyl-2-(3-methylphenyl)-2H-1,2,3-triazol-4-yl]methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 875657-11-7 HCAPLUS


CN Propanoic acid, 2-[4-[[[(2-methoxyethyl)[[5-methyl-2-(3-methylphenyl)-2H-1,2,3-triazol-4-yl]methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 875657-12-8 HCAPLUS


CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(methylamino)-2-oxoethyl][[5-methyl-2-(3-methylphenyl)-2H-1,2,3-triazol-4-yl]methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



● HCl


RN 875657-16-2 HCAPLUS

CN Propanoic acid, 2-[4-[[[[[2-(4-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl][2-(methylamino)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-17-3 HCAPLUS


CN Propanoic acid, 2-[4-[[[[[2-(4-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl][2-(methylamino)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875657-18-4 HCAPLUS

CN Propanoic acid, 2-[4-[[[[[2-(3-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl][2-(methylamino)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 yl)methyl][2-(methylamino)-2-oxoethyl]amino)methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875657-19-5 HCAPLUS  
 CN Propanoic acid, 2-[[[2-(3-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl)methyl][(5-methyl-1,3,4-oxadiazol-2-yl)methyl]amino)methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875657-20-8 HCAPLUS  
 CN Propanoic acid, 2-[[[2-(4-methoxyphenyl)-5-methyl-2H-1,2,3-triazol-4-yl)methyl][(5-methyl-1,3,4-oxadiazol-2-yl)methyl]amino)methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 triazol-4-yl)methyl][2-(methylamino)-2-oxoethyl]amino)methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875657-27-5 HCAPLUS  
 CN Propanoic acid, 2-[[[2-(methoxyethyl)[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino)methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875657-28-6 HCAPLUS  
 CN Propanoic acid, 2-[[[2-(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl][(3,3,3-trifluoropropyl)amino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 875657-21-9 HCAPLUS  
 CN Propanoic acid, 2-[[[2-(4-methoxyphenyl)-5-methyl-2H-1,2,3-triazol-4-yl)methyl][(2-(methylamino)-2-oxoethyl)amino)methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875657-22-0 HCAPLUS  
 CN Propanoic acid, 2-[[[2-(3,4-dimethylphenyl)-5-methyl-2H-1,2,3-triazol-4-yl)methyl][(2-(methylamino)-2-oxoethyl)amino)methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875657-23-1 HCAPLUS  
 CN Propanoic acid, 2-[[[2-(4-(2-methoxyethoxy)phenyl)-5-methyl-2H-1,2,3-triazol-4-yl)methyl][(2-(methylamino)-2-oxoethyl)amino)methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 875657-29-7 HCAPLUS  
 CN Propanoic acid, 2-[[[2-(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl][(3,3,3-trifluoropropyl)amino)methyl]phenoxy]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)




RN 875657-30-0 HCAPLUS  
 CN Propanoic acid, 2-[[[2-(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl][(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

10518347

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 875657-31-1 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(dimethylamino)-2-oxoethyl][(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875657-32-2 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(dimethylamino)-2-oxoethyl][(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 2-A



RN 875657-34-4 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(dimethylamino)-2-oxoethyl][(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875657-35-5 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(dimethylamino)-2-oxoethyl][(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-36-6 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(dimethylamino)-2-oxoethyl][(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)


Page 1208/07/2006

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)





RN 875657-33-3 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(dimethylamino)-2-oxoethyl][(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)


PAGE 1-A





L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875657-37-7 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(dimethylamino)-2-oxoethyl][(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-38-8 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(dimethylamino)-2-oxoethyl][(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 875657-39-9 HCAPLUS  
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-1,3,4-oxadiazol-2-yl)methyl][[1-(4-methylphenyl)-1H-1,2,3-triazol-4-yl)methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 875657-40-2 HCAPLUS  
CN Propanoic acid, 2-[4-[[[(2,2-difluoroethyl)[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI)


875658-56-3P 875658-57-4P 875658-58-5P  
875658-59-6P 875658-60-9P 875658-62-1P  
875658-63-2P 875658-64-3P 875658-65-4P  
875658-69-8P 875658-70-1P 875658-71-2P  
875658-72-3P 875658-73-4P 875658-74-5P  
875658-75-6P 875658-76-7P 875658-77-8P  
875658-78-9P 875658-79-0P 875658-80-3P  
875662-35-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of pyrazole derivs. and other heterocyclic compds. as peroxisome proliferator-activated receptor  $\alpha$  and  $\gamma$  agonists)

RN 875657-47-9 HCAPLUS  
CN Propanoic acid, 2-[4-[[[1-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl)methyl]amino]methyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




PAGE 1-A




PAGE 2-A

RN 875657-53-7 HCAPLUS  
CN Propanoic acid, 2-[2-methoxy-4-[[[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875657-41-3 HCAPLUS  
CN Propanoic acid, 2-[4-[[[(2,2-difluoroethyl)[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, hydrochloride (5:3) (9CI) (CA INDEX NAME)



● 3/5 HCl

IT 875657-47-9P 875657-53-7P 875657-68-4P  
875657-70-8P 875657-71-9P 875657-72-0P  
875657-78-6P 875657-79-7P 875657-80-0P  
875657-82-2P 875657-83-3P 875657-84-4P  
875657-86-6P 875657-88-8P 875657-89-9P  
875657-91-3P 875657-92-4P 875657-93-5P  
875658-03-0P 875658-04-1P 875658-05-2P  
875658-09-6P 875658-10-9P 875658-11-0P  
875658-16-5P 875658-17-6P 875658-18-7P  
875658-21-2P 875658-22-3P 875658-23-4P  
875658-24-5P 875658-25-6P 875658-26-7P  
875658-27-8P 875658-28-9P 875658-29-0P  
875658-30-3P 875658-31-4P 875658-32-5P  
875658-33-6P 875658-34-7P 875658-35-8P  
875658-38-1P 875658-39-2P 875658-40-5P  
875658-41-6P 875658-42-7P 875658-43-8P  
875658-44-9P 875658-45-0P 875658-46-1P  
875658-47-2P 875658-48-3P 875658-49-4P  
875658-50-7P 875658-51-8P 875658-52-9P  
875658-53-0P 875658-54-1P 875658-55-2P


PAGE 1-A



PAGE 2-A




RN 875657-68-4 HCAPLUS  
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 875657-70-8 HCAPLUS  
CN Propanoic acid, 2-[4-[[[(2,2-difluoroethyl)[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


10518347

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 875657-71-9 HCAPLUS

CN Propanoic acid, 2-[4-[[[(carboxymethyl)[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1-ethyl ester (9CI) (CA INDEX NAME)



RN 875657-72-0 HCAPLUS

CN Propanoic acid, 2-[4-[[[(2-acetylhydrazino)-2-oxoethyl][[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875657-78-6 HCAPLUS

CN Propanoic acid, 2-[4-[[[(2-(1,1-dimethylethoxy)-2-oxoethyl)[[(5-methyl-2-(3-methylphenyl)-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 875657-82-2 HCAPLUS

CN Propanoic acid, 2-[4-[[[(2-(4-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl)methyl][2-(1,1-dimethylethoxy)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875657-83-3 HCAPLUS

CN Propanoic acid, 2-[4-[[[(carboxymethyl)[(2-(4-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1-ethyl ester (9CI) (CA INDEX NAME)




RN 875657-84-4 HCAPLUS

CN Propanoic acid, 2-[4-[[[(2-(2-acetylhydrazino)-2-oxoethyl)[(2-(4-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875657-86-6 HCAPLUS

Page 1408/07/2006

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


RN 875657-79-7 HCAPLUS

CN Propanoic acid, 2-[4-[[[(carboxymethyl)[(5-methyl-2-(3-methylphenyl)-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1-ethyl ester (9CI) (CA INDEX NAME)




RN 875657-80-0 HCAPLUS

CN Propanoic acid, 2-[4-[[[(2-(2-acetylhydrazino)-2-oxoethyl)[[(5-methyl-2-(3-methylphenyl)-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Propanoic acid, 2-[4-[[[(2-(3-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl)methyl][2-(1,1-dimethylethoxy)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875657-88-8 HCAPLUS

CN Propanoic acid, 2-[4-[[[(carboxymethyl)[(2-(3-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1-ethyl ester (9CI) (CA INDEX NAME)



RN 875657-89-9 HCAPLUS

CN Propanoic acid, 2-[4-[[[(2-(2-acetylhydrazino)-2-oxoethyl)[(2-(3-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875657-91-3 HCAPLUS


CN Propanoic acid, 2-[4-[[[(2-(1,1-dimethylethoxy)-2-oxoethyl)[(2-(4-

10518347


L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 methoxyphenyl)-5-methyl-2H-1,2,3-triazol-4-yl)methyl]amino)methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 875657-92-4 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(carboxymethyl)[(2-{(4-methoxyphenyl)-5-methyl-1,2,3-triazol-4-yl)methyl]amino)methyl]-2,6-dimethylphenoxy]-2-methyl-, 1-ethyl ester (9CI) (CA INDEX NAME)




RN 875657-93-5 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-(2-acetylhydrazino)-2-oxoethyl)[(2-{(4-methoxyphenyl)-5-methyl-2H-1,2,3-triazol-4-yl)methyl]amino)methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 875658-05-2 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(carboxymethyl)[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino)methyl]-2,6-dimethylphenoxy]-2-methyl-, 1-ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 875658-03-0 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino)methyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 2-A

RN 875658-04-1 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-(1,1-dimethylethoxy)-2-oxoethyl)[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino)methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 875658-09-6 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-(1,1-dimethylethoxy)-2-oxoethyl)[(2-{(3,4-dimethylphenyl)-5-methyl-2H-1,2,3-triazol-4-yl)methyl]amino)methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




10518347

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RN 875658-10-9 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(carboxymethyl)[[2-(3,4-dimethylphenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1-ethyl ester (9CI) (CA INDEX NAME)




RN 875658-11-0 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(2-acetylhydrazino)-2-oxoethyl][[2-(3,4-dimethylphenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875658-16-5 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(1,1-dimethylethoxy)-2-oxoethyl][[1-(4-methylphenyl)-1H-1,2,3-triazol-4-yl]methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 875658-17-6 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(carboxymethyl)[[1-(4-methylphenyl)-1H-1,2,3-triazol-4-yl]methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1-ethyl ester (9CI) (CA INDEX NAME)




RN 875658-18-7 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(2-acetylhydrazino)-2-oxoethyl][[1-(4-methylphenyl)-1H-1,2,3-triazol-4-yl]methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 875658-21-2 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[1-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]methyl][2-furanylmethyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875658-22-3 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(furanylmethyl)[[3-methyl-1-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl]methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 875658-23-4 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(furanylmethyl)[[3-methyl-1-phenyl-1H-pyrazol-4-yl]methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875658-24-5 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(furanylmethyl)[[3-methyl-1-phenyl-1H-pyrazol-4-yl]methyl]amino]methyl]-2-methoxyphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)







RN 875658-25-6 HCAPLUS  
CN Propanoic acid, 2-[4-[[[1-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]methyl](2-furanylmethyl)amino]methyl]-2-methoxyphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875658-26-7 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl]methyl](2-furanylmethyl)amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875658-27-8 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl]methyl](2-furanylmethyl)amino]methyl]-2-methoxyphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875658-28-9 HCAPLUS  
CN Propanoic acid, 2-[4-[[[1-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]methyl](2-thiazolymethyl)amino]methyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 875658-29-0 HCAPLUS  
CN Propanoic acid, 2-[4-[[[2-furanylmethyl][4-methyl-1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 875658-30-3 HCAPLUS  
CN Propanoic acid, 2-[4-[[[2-furanylmethyl][1-[4-(trifluoromethyl)phenyl]-1H-indazol-4-yl]methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875658-31-4 HCAPLUS  
CN Propanoic acid, 2-[2-methoxy-4-[[[3-methyl-1-phenyl-1H-pyrazol-4-yl]methyl](2-oxazolymethyl)amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875658-32-5 HCAPLUS  
CN Propanoic acid, 2-[4-[[[2-furanylmethyl][1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]amino]methyl]-2-methoxyphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

10518347

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 875658-33-6 HCAPLUS  
 CN Propanoic acid, 2-[(4-[(2-furanylmethyl){(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl}amino)methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875658-34-7 HCAPLUS  
 CN Propanoic acid, 2-[(4-[(2-furanylmethyl){(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl}amino)methyl]-2-methoxyphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 875658-35-8 HCAPLUS  
 CN Propanoic acid, 2-[(4-[(2-furanylmethyl){(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl}amino)methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 875658-38-1 HCAPLUS  
 CN Propanoic acid, 2-[(2-methoxy-4-[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl][(2-(trifluoromethyl)phenyl)methyl]amino)methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 875658-39-2 HCAPLUS  
 CN Propanoic acid, 2-[(2-methoxy-4-[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl][(2-(trifluoromethyl)phenyl)methyl]amino)methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A




PAGE 2-A



RN 875658-40-5 HCAPLUS  
 CN Propanoic acid, 2-[(4-[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl][(2-furanylmethyl)amino)methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RN 875658-41-6 HCAPLUS  
 CN Propanoic acid, 2-[2-methoxy-4-[[[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl](3,3,3-trifluoropropyl)amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




PAGE 1-A




PAGE 2-A

RN 875658-42-7 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(3-(4-fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)methyl](2-furanylmethyl)amino]methyl]-2-methoxyphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 875658-43-8 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-amino-2-oxoethyl)[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875658-44-9 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(2-(methylamino)-2-oxoethyl)[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 875658-45-0 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-(dimethylamino)-2-oxoethyl)[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875658-46-1 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-1,3,4-oxadiazol-2-yl)methyl][(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)





RN 875658-47-2 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(3-methoxypropyl)[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 875658-48-3 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-methoxyethyl)[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 875658-49-4 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-methoxyethyl)[(5-methyl-2-(4-methylphenyl)-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 875658-50-7 HCAPLUS

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(methylamino)-2-oxoethyl][[5-methyl-2-(4-methylphenyl)-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 875658-51-8 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[5-methyl-2-(4-methylphenyl)-2H-1,2,3-triazol-4-yl)methyl][[5-methyl-1,3,4-oxadiazol-2-yl)methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875658-52-9 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-methoxypropyl][[5-methyl-2-(4-methylphenyl)-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[5-methyl-2-(3-methylphenyl)-2H-1,2,3-triazol-4-yl)methyl][[5-methyl-1,3,4-oxadiazol-2-yl)methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 875658-56-3 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-methoxypropyl][[5-methyl-2-(3-methylphenyl)-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875658-57-4 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(4-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl)methyl][2-(methylamino)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 875658-58-5 HCAPLUS


L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 875658-53-0 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-methoxyethyl][[5-methyl-2-(3-methylphenyl)-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 875658-54-1 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(methylamino)-2-oxoethyl][[5-methyl-2-(3-methylphenyl)-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 875658-55-2 HCAPLUS

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 CN Propanoic acid, 2-[4-[[[2-(4-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl)methyl][[5-methyl-1,3,4-oxadiazol-2-yl)methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875658-59-6 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl)methyl][2-(methylamino)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 875658-60-9 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl)methyl][[5-methyl-1,3,4-oxadiazol-2-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

10518347

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 875658-62-1 HCAPLUS  
CN Propanoic acid, 2-[[[2-(4-methoxyphenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl][(5-methyl-1,3,4-oxadiazol-2-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875658-63-2 HCAPLUS  
CN Propanoic acid, 2-[[[2-(4-methoxyphenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl][(2-methylamino)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 875658-64-3 HCAPLUS  
CN Propanoic acid, 2-[[[2-(3,4-dimethylphenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl][2-(methylamino)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 875658-65-4 HCAPLUS  
CN Propanoic acid, 2-[[[2-(4-(2-methoxyethoxy)phenyl)-5-methyl-2H-1,2,3-triazol-4-yl]methyl][2-(methylamino)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

—OBu-t

RN 875658-69-8 HCAPLUS

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
CN Propanoic acid, 2-[[[2-(2-methoxyethyl)[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 2-A

RN 875658-70-1 HCAPLUS  
CN Propanoic acid, 2-[[[2-(2-methoxyethyl)[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




PAGE 1-A

PAGE 2-A

RN 875658-71-2 HCAPLUS  
CN Propanoic acid, 2-[[[2-(2-methoxyethyl)[(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


RN 875658-72-3 HCAPLUS  
 CN Propanoic acid, 2-[[4-[[[(5-isoxazolyl)methyl][(3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




PAGE 2-A



RN 875658-74-5 HCAPLUS  
 CN Propanoic acid, 2-[[4-[[[(2-(3,4-dimethylphenyl)-5-methyl-2H-1,2,3-triazol-4-yl)methyl][(5-methyl-1,3,4-oxadiazol-2-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 875658-75-6 HCAPLUS  
 CN Propanoic acid, 2-[[4-[[[(2-(4-chlorophenyl)-5-methyl-2H-1,2,3-triazol-4-yl)methyl][(2-methoxyethyl)amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)






RN 875658-76-7 HCAPLUS  
 CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[(2-(4-methoxyphenyl)-5-methyl-2H-

PAGE 1-A




RN 875658-73-4 HCAPLUS  
 CN Propanoic acid, 2-[[4-[[[(1-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl)methyl][(2-(methylamino)-2-oxoethyl)amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





RN 875658-77-8 HCAPLUS  
 CN Propanoic acid, 2-[[4-[[[(2-hydroxyethyl)[(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 875658-78-9 HCAPLUS  
 CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[(1-(4-methylphenyl)-1H-1,2,3-triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

10518347

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 875658-79-0 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[5-methyl-1,3,4-oxadiazol-2-yl)methyl][[1-(4-methylphenyl)-1H-1,2,3-triazol-4-yl)methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 875658-80-3 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2,2-difluoroethyl)[(5-methyl-2-phenyl-2H-1,2,3-


L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 triazol-4-yl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 875662-35-4 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(methylamino)-2-oxoethyl][3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




L4 ANSWER 4 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 09 Dec 2005  
 AB The use of a PPAR agonist is disclosed in the manufacture of a medicament to increase ruminant serum glucose concns., and preferably, for the palliative, prophylactic or curative treatment of ruminant disease associated with reduced serum glucose concentration. The ruminant disease associated with reduced serum glucose concentration includes fatty liver syndrome, dystocia, immune dysfunction, impaired immune function, toxification, primary ketosis, secondary ketosis, downer cow syndrome, indigestion, inappetence, retained placenta, displaced abomasum, mastitis, endometritis, infertility, low fertility, lameness, subacute rumen acidosis and inadequate nutrient intake associated with stress, e.g., heat, poor housing, overcrowding, shipping, dominance or illness. Thus, a solution contained a PPAR agonist 1-750 mg/5 mL.  
 ACCESSION NUMBER: 2005:1291851 HCAPLUS  
 DOCUMENT NUMBER: 144:27602  
 TITLE: PPAR agonists for increasing serum glucose concentrations  
 INVENTOR(S): Goetze, Leopold Franz; Kehrl, Marcus Eugene, Jr.; Ricketts, Anthony Paul; Taube, Patrick Carl  
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
 SOURCE: PCT Int. Appl., 64 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115369	A2	20051208	WO 2005-1B1501	20050513
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPL. INFO.: US 2004-574136P P 20040525 IT 343321-96-0 343322-19-0 343322-23-6 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (PPAR agonists for increasing serum glucose concns.) RN 343321-96-0 HCAPLUS CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)				


10518347

L4 ANSWER 4 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 343322-19-0 HCAPLUS


CN Propanoic acid, 2-[4-[[[2-(4-ethylphenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 343322-23-6 HCAPLUS

CN Propanoic acid, 2-[4-[[[2-(4-fluorophenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 5 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 20 Oct 2005

AB This invention relates to a method of formulating dosage forms of pharmaceutically active ingredients and to solid dosage forms produced thereby wherein the dosage form contains a very low dose, more especially an ultra-low dose of the active ingredients. Tablets were obtained containing

10  $\mu$ g 2-methyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]thiazol-5-ylcarbonyl]amino]methyl]phenoxy]propionic acid by a high-shear granulation process.

ACCESSION NUMBER: 2005:1123733 HCAPLUS

DOCUMENT NUMBER: 143:393026

TITLE: Low dose pharmaceutical products

INVENTOR(S): Faulkner, Patrick; Fan, Rennan; Provot, Gerard

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXX02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097076	A2	20051020	WO 2005-EP3722	20050407
WO 2005097076	A3	20060105		

V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPL. INFO.: US 2004-561235P P 20040409


IT 343321-96-0

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(low dose pharmaceutical products)

RN 343321-96-0 HCAPLUS

CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)





10518347

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 14 Oct 2005  
 GI



AB Title compds. I [Q = optionally substituted benzene, pyridine with OH, halo, alkenyl, etc.; R1 = optionally substituted Ph, pyridyl, pyrimidinyl, etc. with halo, alkenyl, alkoxy, etc.; R2 = optionally substituted pyridyl, pyrimidinyl, pyrazinyl, etc. with OH, halo, alkenyl, etc.; X, Y, Z = C, O, S, etc.; R3-R6 = H, alkyl, etc.; R7-R9 = H, alkyl; n = 0-3] were prepared for example, reductive amination of 2-formylthiazole with compound II [R = H; OR' = tert-butoxy], e.g., prepared from 2-(3-bromophenyl)-4-chloromethyl-5-methylphenylloxazole in 4 steps, followed by treatment with HCl afforded compound II [R = thiazol-2-ylmethyl; OR' = OH] hydrochloride salt. In GAL4-hPPAR transactivation assays, compound II [R = thiazol-2-ylmethyl; OR' = OH] hydrochloride salt showed the EC50 value of 0.013  $\mu$ M for PPAR $\alpha$ . Of note, compds. I are useful as PPAR  $\alpha/\gamma$  agonists for the treatment of diabetes.

ACCESSION NUMBER: 2005:1103761 HCAPLUS  
 DOCUMENT NUMBER: 143:387018  
 TITLE: Preparation of oxazole compounds containing phenoxyacetic acid moiety as PPAR  $\alpha/\gamma$  agonists  
 INVENTOR(S): Kagechika, Hiroyuki; Shibata, Yoshihiro; Oguri, Atsushi  
 PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co. Ltd., Japan  
 SOURCE: PCT Int. Appl., 171 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

WO 2005095364 A1 20051013 WO 2005-JP5740 20050328  
 WO 2005095364 C1 20060105

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SE, TZ, UG, ZH, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2004-99201 A 20040330  
 JP 2005-15954 A 20050124

OTHER SOURCE(S): MARPAT 143:387018

IT 866639-46-5P 866639-48-7P 866639-50-1P  
 866639-52-3P 866639-56-7P 866639-59-0P  
 866639-61-4P 866639-63-6P 866639-65-8P  
 866639-67-0P 866639-70-5P 866639-73-8P  
 866639-75-0P 866639-77-2P 866639-79-4P  
 866639-81-8P 866639-83-0P 866639-85-2P  
 866639-87-4P 866639-89-6P 866639-93-2P  
 866639-95-4P 866639-97-6P 866639-99-8P  
 866640-01-9P 866640-07-3P 866640-09-7P  
 866640-11-1P 866640-13-3P 866640-15-5P  
 866640-17-7P 866640-25-7P 866640-27-9P  
 866640-29-1P 866640-31-5P 866640-33-7P  
 866640-35-9P 866640-43-9P 866640-47-3P  
 866640-49-5P 866640-51-9P 866640-52-0P  
 866640-54-2P 866640-58-6P 866640-61-1P  
 866640-63-3P 866640-65-5P 866640-67-7P  
 866640-70-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (Preparation of oxazole compds. containing phenoxyacetic acid moiety as


PPAR

$\alpha/\gamma$  agonists)


RN 866639-46-5 HCAPLUS

CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl](4-thiazolylmethyl)amino]methyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 866639-48-7 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl](1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866639-50-1 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl](1-methyl-1H-benzimidazol-2-yl)methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 866639-52-3 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl](4-pyridinylmethyl)amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866639-56-7 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl](4-pyridinylmethyl)amino]methyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 866639-59-0 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl]amino]methyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 866639-61-4 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl]amino]methyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 866639-67-0 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl]amino]methyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 866639-70-5 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl]amino]methyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 866639-73-8 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl]amino]methyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 866639-63-6 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl]amino]methyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 866639-65-8 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl]amino]methyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 866639-75-0 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866639-77-2 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866639-79-4 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl]amino]methyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
oxazolyl)methyl]amino)methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866639-81-8 HCAPLUS  
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-2-phenyl-4-oxazolyl)methyl]amino)methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866639-83-0 HCAPLUS  
CN Propanoic acid, 2-[4-[[[(4,5-dihydro-5-oxo-1,3,4-oxadiazol-2-yl)methyl] [(5-methyl-2-phenyl-4-oxazolyl)methyl]amino)methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 866639-89-6 HCAPLUS  
CN Hexanoic acid, 2-[4-[[[(5-methyl-2-phenyl-4-oxazolyl)methyl] [(2-oxazolyl)methyl]amino)methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 866639-93-2 HCAPLUS  
CN Propanoic acid, 2-[4-[[[(2-benzoxazolyl)methyl] [(5-methyl-2-phenyl-4-oxazolyl)methyl]amino)methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 866639-85-2 HCAPLUS  
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-1,3,4-oxadiazol-2-yl)methyl] [(5-methyl-2-phenyl-4-oxazolyl)methyl]amino)methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866639-87-4 HCAPLUS  
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(3-methyl-1,2,4-oxadiazol-5-yl)methyl] [(5-methyl-2-phenyl-4-oxazolyl)methyl]amino)methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 866639-95-4 HCAPLUS  
CN Propanoic acid, 2-[4-[[[bis[(5-methyl-2-phenyl-4-oxazolyl)methyl]amino)methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866639-97-6 HCAPLUS  
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(4-methyl-2-oxazolyl)methyl] [(5-methyl-2-phenyl-4-oxazolyl)methyl]amino)methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 866639-99-8 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-(((2-oxazolymethyl)((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)amino)methyl)phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866640-01-9 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-(((2-oxazolymethyl)((5-phenyl-2-oxazolyl)methyl)amino)methyl)phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 866640-07-5 HCAPLUS  
 CN Propanoic acid, 2-[2-fluoro-6-methoxy-4-(((5-methyl-2-phenyl-4-oxazolyl)methyl)(2-oxazolymethyl)amino)methyl)phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866640-09-7 HCAPLUS  
 CN Propanoic acid, 2-[2-methoxy-6-methyl-4-(((5-methyl-2-phenyl-4-oxazolyl)methyl)(2-oxazolymethyl)amino)methyl)phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 866640-11-1 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-(((5-methyl-2-(4-methylphenyl)-4-oxazolyl)methyl)((5-methyl-1,3,4-oxadiazol-2-yl)methyl)amino)methyl)phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866640-13-3 HCAPLUS  
 CN Propanoic acid, 2-[4-(((2-(4-chlorophenyl)-5-methyl-4-oxazolyl)methyl)((5-methyl-1,3,4-oxadiazol-2-yl)methyl)amino)methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 866640-15-5 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-(((3-phenyl-1,2,4-oxadiazol-5-yl)methyl)(2-thiazolymethyl)amino)methyl)phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866640-17-7 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-(((5-phenyl-2-oxazolyl)methyl)(2-thiazolymethyl)amino)methyl)phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 866640-25-7 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-(((5-methyl-2-oxazolyl)methyl)((3-phenyl-1,2,4-oxadiazol-5-yl)methyl)amino)methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866640-27-9 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-(((5-methyl-2-oxazolyl)methyl)((5-phenyl-2-oxazolyl)methyl)amino)methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866640-35-9 HCAPLUS  
 CN Propanoic acid, 2-[2-methoxy-6-methyl-4-(((2-(methylamino)-2-oxoethyl)((5-methyl-2-phenyl-4-oxazolyl)methyl)amino)methyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 866640-43-9 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-(((2-oxazolyl)methyl)((5-phenyl-3-isoxazolyl)methyl)amino)methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866640-47-3 HCAPLUS  
 CN Propanoic acid, 2-[2-ethyl-6-methyl-4-(((5-methyl-2-phenyl-4-oxazolyl)methyl)((2-oxazolyl)methyl)amino)methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866640-29-1 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-(((2-(methylamino)-2-oxoethyl)((5-methyl-2-(4-methylphenyl)-4-oxazolyl)methyl)amino)methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866640-31-5 HCAPLUS  
 CN Propanoic acid, 2-[4-(((2-(4-chlorophenyl)-5-methyl-4-oxazolyl)methyl)((2-(methylamino)-2-oxoethyl)amino)methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866640-33-7 HCAPLUS  
 CN Propanoic acid, 2-[4-(((2-(3-chlorophenyl)-5-methyl-4-oxazolyl)methyl)((2-(methylamino)-2-oxoethyl)amino)methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 866640-49-5 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-(((5-methyl-2-phenyl-4-oxazolyl)methyl)((5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)methyl)amino)methyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 866640-51-9 HCAPLUS  
 CN Propanoic acid, 2-[4-(((4,5-dihydro-5-oxo-1,3,4-oxadiazol-2-yl)methyl)((5-methyl-2-phenyl-4-oxazolyl)methyl)amino)methyl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 866640-52-0 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(4,5-dihydro-4-methyl-5-oxo-1,3,4-oxadiazol-2-yl)methyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 866640-54-2 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2,6-difluoro-4-[[[(5-methyl-2-phenyl-4-oxazolyl)methyl][(2-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 866640-58-6 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methyl][(3-methyl-1,2,4-oxadiazol-5-yl)methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866640-61-1 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-cyclopropylamino)-2-oxoethyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866640-63-3 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-(cyclopropylmethyl)amino)-2-oxoethyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866640-65-5 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-amino-2-oxoethyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 866640-67-7 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-2-phenyl-4-oxazolyl)methyl][(5-(3-pyridinyl)-1,3,4-oxadiazol-2-yl)methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 866640-70-2 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-amino-2-oxoethyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



IT 866639-47-6P 866639-49-8P 866639-51-2P  
 866639-55-6P 866639-57-8P 866639-60-3P  
 866639-62-5P 866639-64-7P 866639-66-9P  
 866639-69-2P 866639-72-7P 866639-74-9P  
 866639-76-1P 866639-78-3P 866639-80-7P  
 866639-82-9P 866639-84-1P 866639-86-3P  
 866639-88-5P 866639-90-9P 866639-94-3P  
 866639-96-5P 866639-98-7P 866640-00-8P  
 866640-02-0P 866640-08-6P 866640-10-0P  
 866640-12-2P 866640-14-4P 866640-16-6P  
 866640-18-8P 866640-26-8P 866640-28-0P  
 866640-30-4P 866640-32-6P 866640-34-8P  
 866640-36-0P 866640-37-1P 866640-38-2P  
 866640-39-3P 866640-40-6P 866640-44-0P  
 866640-45-1P 866640-46-2P 866640-48-4P  
 866640-50-8P 866640-53-1P 866640-55-3P  
 866640-59-7P 866640-62-2P 866640-64-4P  
 866640-66-6P 866640-68-8P 866640-69-9P

RI: PAC (Pharmacological activity), SPN (Synthetic preparation), THU (Therapeutic use), BIOL (Biological study), PREP (Preparation), USES (Uses)


PPAR (preparation of oxazole compds. containing phenoxyacetic acid moiety as

10518347

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 866639-47-6 HCAPLUS


CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl](2-thiazolylmethyl)amino]methyl]phenoxy]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 866639-49-8 HCAPLUS


CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl](1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 866639-51-2 HCAPLUS

CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl](1-methyl-1H-benzimidazol-2-yl)methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● x HCl

RN 866639-60-3 HCAPLUS

CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl](2-methyl-4-thiazolyl)methyl]amino]methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 866639-62-5 HCAPLUS


CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl](3,5-dimethyl-4-isoxazolyl)methyl]amino]methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866639-55-6 HCAPLUS


CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl](4-pyridinylmethyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 866639-57-8 HCAPLUS

CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl](4-thiazolylmethyl)amino]methyl]phenoxy]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 866639-64-7 HCAPLUS

CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl](2-methylamino)-2-oxoethyl]amino]methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 866639-66-9 HCAPLUS

CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl](2-(dimethylamino)-2-oxoethyl)amino]methyl]phenoxy]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)

10518347

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● x HCl

RN 866639-69-2 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[[[2-(methylamino)-2-oxoethyl]({5-methyl-2-phenyl-4-oxazolyl)methyl}amino)methyl]-2-(2-propenyl)phenoxy]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 866639-68-1  
 CMF C28 H33 N3 O5



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 866639-76-1 HCAPLUS  
 CN Propanoic acid, 2-[[2,6-dimethyl-4-[[[2-(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]phenoxy]-2-methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 866639-78-3 HCAPLUS  
 CN Propanoic acid, 2-[[2,6-dimethyl-4-[[[2-(methylamino)-2-oxoethyl]({5-methyl-2-phenyl-4-oxazolyl)methyl}amino)methyl]phenoxy]-2-methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866639-72-7 HCAPLUS  
 CN Propanoic acid, 2-[[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl]({2-(methylamino)-2-oxoethyl}amino)methyl]-2-(2-propenyl)phenoxy]-2-methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 866639-71-6  
 CMF C28 H32 Br N3 O5




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 866639-74-9 HCAPLUS  
 CN Propanoic acid, 2-[[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methyl]({2-oxazolylmethyl}amino)methyl]phenoxy]-2-methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866639-80-7 HCAPLUS  
 CN Propanoic acid, 2-[[4-[[[2-(dimethylamino)-2-oxoethyl]({5-methyl-2-phenyl-4-oxazolyl)methyl}amino)methyl]-2,6-dimethylphenoxy]-2-methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 866639-82-9 HCAPLUS  
 CN Propanoic acid, 2-[[2,6-dimethyl-4-[[[2-(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]phenoxy]-2-methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 866639-84-1 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(4,5-dihydro-5-oxo-1,3,4-oxadiazol-2-yl)methyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, (9CI) (CA INDEX NAME)




RN 866639-86-3 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-1,3,4-oxadiazol-2-yl)methyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]phenoxy]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● x HCl


RN 866639-94-3 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-benzoxazolyl)methyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 866639-96-5 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[bis[(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● H HCl


RN 866639-88-5 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(3-methyl-1,2,4-oxadiazol-5-yl)methyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 866639-90-9 HCAPLUS  
 CN Hexanoic acid, 2-[4-[[[(5-methyl-2-phenyl-4-oxazolyl)methyl][(2-oxazolyl)methyl]amino]methyl]phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 866639-98-7 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(4-methyl-2-oxazolyl)methyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 866640-00-8 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(2-oxazolyl)methyl][(5-phenyl-1,3,4-oxadiazol-2-yl)methyl]amino]methyl]phenoxy]-2-methyl-, hydrochloride (4:1) (9CI) (CA INDEX NAME)


10518347

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 1/4 HCl


RN 866640-02-0 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(2-oxazolymethyl)((5-phenyl-2-oxazolyl)methyl]amino)methyl]phenoxy]-2-methyl-, hydrochloride (4:3) (9CI) (CA INDEX NAME)



● 3/4 HCl


RN 866640-08-6 HCAPLUS  
 CN Propanoic acid, 2-[2-fluoro-6-methoxy-4-[[[(5-methyl-2-phenyl-4-oxazolyl)methyl](2-oxazolymethyl)amino)methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl


RN 866640-10-0 HCAPLUS  
 CN Propanoic acid, 2-[2-methoxy-6-methyl-4-[[[(5-methyl-2-phenyl-4-oxazolyl)methyl](2-oxazolymethyl)amino)methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 866640-12-2 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methyl](2-oxazolymethyl)amino)methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 866640-14-4 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-(4-chlorophenyl)-5-methyl-4-oxazolyl)methyl][(5-methyl-1,3,4-oxadiazol-2-yl)methyl]amino)methyl]-2,6-dimethylphenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN 866640-16-6 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl](2-thiazolymethyl)amino)methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 866640-18-8 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-phenyl-2-oxazolyl)methyl](2-thiazolymethyl)amino)methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 866640-26-8 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-2-oxazolyl)methyl][(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]amino)methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


10518347

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● x HCl


RN 866640-28-0 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(5-methyl-2-oxazolyl)methyl][(5-phenyl-2-oxazolyl)methyl]amino]methyl]phenoxy]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 866640-30-4 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(methylamino)-2-oxoethyl][(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methyl]amino]methyl]phenoxy]-2-methyl-, (CA INDEX NAME)


L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866640-37-1 HCAPLUS  
 CN Propanoic acid, 2-[2-methoxy-6-methyl-4-[[[2-(5-methyl-2-phenyl-4-oxazolyl)methyl](2-thiazolylmethyl)amino]methyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 866640-38-2 HCAPLUS  
 CN Propanoic acid, 2-[2-methoxy-6-methyl-4-[[[2-(5-methyl-2-phenyl-4-oxazolyl)methyl](2-thiazolylmethyl)amino]methyl]phenoxy]-2-methyl-, (CA INDEX NAME)




RN 866640-39-3 HCAPLUS  
 CN Propanoic acid, 2-[2-fluoro-4-[[[2-(5-methyl-2-phenyl-4-oxazolyl)methyl](2-


L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866640-32-6 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl)methyl][2-(methylamino)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, (9CI) (CA INDEX NAME)




RN 866640-34-8 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl)methyl][2-(methylamino)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, (9CI) (CA INDEX NAME)




RN 866640-36-0 HCAPLUS  
 CN Propanoic acid, 2-[2-methoxy-6-methyl-4-[[[2-(methylamino)-2-oxoethyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]phenoxy]-2-methyl-, (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 oxazolylmethyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 866640-40-6 HCAPLUS  
 CN Propanoic acid, 2-[2-fluoro-4-[[[2-(5-methyl-2-phenyl-4-oxazolyl)methyl](2-oxazolylmethyl)amino]methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 866640-44-0 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(oxazolylmethyl)(5-phenyl-3-isoxazolyl)methyl]amino]methyl]phenoxy]-2-methyl-, (9CI) (CA INDEX NAME)

10518347

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 866640-45-1 HCAPLUS  
CN Propanoic acid, 2-[2-ethyl-4-[[[(5-methyl-2-phenyl-4-oxazolyl)methyl](2-oxazolylmethyl)amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866640-46-2 HCAPLUS  
CN Propanoic acid, 2-[2-ethyl-4-[[[(5-methyl-2-phenyl-4-oxazolyl)methyl](2-oxazolylmethyl)amino]methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl


RN 866640-48-4 HCAPLUS  
CN Propanoic acid, 2-[2-ethyl-6-methyl-4-[[[(5-methyl-2-phenyl-4-oxazolyl)methyl](2-oxazolylmethyl)amino]methyl]phenoxy]-2-methyl-, hydrochloride (20:17) (9CI) (CA INDEX NAME)



● 17/20 HCl


RN 866640-50-8 HCAPLUS  
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-2-phenyl-4-oxazolyl)methyl]([5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)methyl]amino]methyl]phenoxy]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● x HCl

RN 866640-53-1 HCAPLUS  
CN Propanoic acid, 2-[4-[[[(4,5-dihydro-4-methyl-5-oxo-1,3,4-oxadiazol-2-yl)methyl]([5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)




RN 866640-55-3 HCAPLUS  
CN Propanoic acid, 2-[2,6-difluoro-4-[[[(5-methyl-2-phenyl-4-oxazolyl)methyl](2-oxazolylmethyl)amino]methyl]phenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● HCl

RN 866640-59-7 HCAPLUS  
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methyl]([3-methyl-1,2,4-oxadiazol-5-yl)methyl]amino]methyl]phenoxy]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)




RN 866640-62-2 HCAPLUS  
CN Propanoic acid, 2-[4-[[[(2-cyclopropylamino)-2-oxoethyl]([5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866640-64-4 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(cyclopropylmethyl)amino]-2-oxoethyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 866640-66-6 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(butylamino)-2-oxoethyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 866640-68-8 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 866640-74-6 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl)methyl]amino]methyl]phenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 866640-75-7 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl)methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866640-76-8 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl)methyl]amino]methyl]phenoxy]-2-methyl-, 1-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 866640-78-0 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl)methyl]amino]methyl]-2-(2-propenyl)phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 oxazolyl)methyl][(5-(3-pyridinyl)-1,3,4-oxadiazol-2-yl)methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 866640-69-9 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-amino-2-oxoethyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




IT 866640-74-6P 866640-75-7P 866640-76-8P  
 866640-78-0P 866640-79-1P 866640-80-4P  
 866640-81-5P 866640-85-9P 866640-86-0P  
 866640-88-2P 866640-89-3P 866640-90-6P  
 866640-93-9P 866640-95-1P 866640-96-2P  
 866641-17-0P 866641-18-1P 866641-19-2P  
 866641-20-5P 866641-21-6P 866641-22-7P  
 866641-24-9P 866641-25-0P 866641-29-4P  
 866641-30-7P 866641-31-8P 866641-32-9P  
 866641-33-0P 866641-41-0P  
 RL: RCT (Reactant); SPW (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of oxazole compds. containing phenoxyacetic acid moiety as  
 PPAP a/y agonists)


L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 866640-79-1 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl)methyl]amino]methyl]-2-(2-propenyl)phenoxy]-2-methyl-, 1-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 866640-80-4 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl)methyl]amino]methyl]-2-(2-propenyl)phenoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 866640-81-5 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-bromophenyl)-5-methyl-4-oxazolyl)methyl]amino]methyl]-2-(2-propenyl)phenoxy]-2-methyl-, 1-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RN 866640-85-9 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(1,1-dimethylethoxy)-2-oxoethyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866640-86-0 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(carboxymethyl)[(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1-ethyl ester, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 866640-88-2 HCAPLUS  
 CN Hydrazinecarboxylic acid, 2-[[[4-(2-ethoxy-1,1-dimethyl-2-oxoethoxy)-3,5-dimethylphenyl]methyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 866640-89-3 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(2-hydrazino-2-oxoethyl)[(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester


L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 866641-96-2 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-[(1-methyl-2-oxoethyl)amino]-2-oxoethyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866641-17-0 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-[(1,1-dimethylethoxy)-2-oxoethyl][(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866641-18-1 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(carboxymethyl)[(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1-ethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 (9CI) (CA INDEX NAME)



RN 866640-90-6 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(2-acetylhydrazino)-2-oxoethyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866640-93-9 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[2-(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866640-95-1 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-[(2-hydroxy-1-methylethyl)amino]-2-oxoethyl][(5-methyl-2-phenyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 866641-19-2 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-[(4-chlorophenyl)-5-methyl-4-oxazolyl]methyl]-2-(1,1-dimethylethoxy)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 866641-20-5 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(carboxymethyl)[(2-(4-chlorophenyl)-5-methyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1-ethyl ester (9CI) (CA INDEX NAME)




RN 866641-21-6 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-[(3-chlorophenyl)-5-methyl-4-oxazolyl]methyl]-2-(1,1-dimethylethoxy)-2-oxoethyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 866641-22-7 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(carboxymethyl)[(2-(3-chlorophenyl)-5-methyl-4-oxazolyl)methyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, 1-ethyl ester (9CI) (CA INDEX NAME)

10518347


L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866641-24-9 HCAPLUS  
 CN Propanoic acid, 2-[2-methoxy-6-methyl-4-(((5-methyl-2-phenyl-4-oxazolyl)methyl)amino)methyl]phenoxyl-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 866641-25-0 HCAPLUS  
 CN Propanoic acid, 2-[4-(((carboxymethyl){(5-methyl-2-phenyl-4-oxazolyl)methyl}amino)methyl]phenoxyl-2-methoxy-6-methylphenoxyl-2-methyl-, 1-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 866641-29-4 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-(((5-methyl-2-phenyl-4-oxazolyl)methyl)amino)methyl]phenoxyl-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 866641-30-7 HCAPLUS  
 CN Propanoic acid, 2-[4-(((carboxymethyl){(5-methyl-2-phenyl-4-oxazolyl)methyl}amino)methyl]phenoxyl-2,6-dimethylphenoxyl-2-methyl-, 1-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 866641-31-8 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-(((5-methyl-2-phenyl-4-oxazolyl)methyl)amino)methyl]phenoxyl-2-methoxy-6-methylphenoxyl-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 866641-32-9 HCAPLUS  
 CN Hydrazinecarboxylic acid, 2-[[[4-[[2-(1,1-dimethylethoxy)-1,1-dimethyl-2-oxoethoxy]-3,5-dimethylphenyl]methyl]((5-methyl-2-phenyl-4-oxazolyl)methyl)amino]acetyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 866641-33-0 HCAPLUS  
 CN Propanoic acid, 2-[4-(((2-hydrazino-2-oxoethyl){(5-methyl-2-phenyl-4-oxazolyl)methyl}amino)methyl]phenoxyl-2,6-dimethylphenoxyl-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 866641-41-0 HCAPLUS  
 CN 3-Pyridinecarboxylic acid, 2-[[[4-[[2-(ethoxy-1,1-dimethyl-2-oxoethoxy)-3,5-dimethylphenyl]methyl]((5-methyl-2-phenyl-4-oxazolyl)methyl)amino]acetyl]h

L4 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 28 HCAPLUS COPYRIGHT 2006 ACS ON STN

ED Entered STN: 16 Aug 2005

AB Thiazole and thiadiazole analogs have been recently proposed as a novel promising class of adenosine A1 and A3 receptor antagonists. When appropriately modified, they show selectivity toward A1 or A3 receptors, which results in a variety of therapeutic potentialities of these ligands. In this work, we carried out a QSAR study on thiazole and thiadiazole analogs as antagonists for adenosine A1 and A3 receptors. To develop reliable models, we focused attention on any possible pitfalls of each step of QSAR process and approached each stage following accurate procedures. Application of datasets by using CODESSA software led to QSAR equations based on three and four descriptors for the adenosine A1 and A3 receptor ligands, resp. The obtained models allowed us to understand the main structural features that strongly correlate with the target property.

ACCESSION NUMBER: 2005:777992 HCAPLUS

DOCUMENT NUMBER: 143:278405

TITLE: QSAR study on thiazole and thiadiazole analogues as antagonists for the adenosine A1 and A3 receptors

AUTHOR(S): Borghini, Alice; Pietra, Daniele; Domenichelli,

Patrick; Bianucci, Anna Maria

CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Università di

Pisa, Pisa, 56126, Italy

SOURCE: Bioorganic &amp; Medicinal Chemistry (2005), 13(18),

5330-5337

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 331472-35-6

RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)

(QSAR study on thiazole and thiadiazole analogs as antagonists for adenosine A1 and A3 receptors)

RN 331472-35-6 HCAPLUS

CN Acetic acid, [4-[[[3-phenyl-1,2,4-thiadiazol-5-yl]amino]carbonyl]phenoxy]-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 28 HCAPLUS COPYRIGHT 2006 ACS ON STN

ED Entered STN: 09 Aug 2005

AB The combination of mol. electrostatic potential (MEP) surface properties (autocorrelation vectors) with the conventional partial least squares (PLS) anal. has been used for the prediction of the human A3 receptor antagonist activities. Three-hundred-fifty-eight structurally diverse human A3 receptor antagonists have been utilized to generate a novel ligand-based three-dimensional structure-activity relation. Remarkably, our chemical library includes all 21 important chemical classes of human A3 antagonists currently discovered, and it represents the largest mol. collection used to generate a general human A3 antagonist structure-activity relation. A robust quant. model has been obtained as described by both cross-validated correlation coefficient (rcv = 0.81) and prediction capability (rpred = 0.82). The proposed MEP/PLS approach can be considered as an alternative hit identification tool in virtual screening applications.

ACCESSION NUMBER: 2005:703873 HCAPLUS

DOCUMENT NUMBER: 143:338940

TITLE: Autocorrelation of Molecular Electrostatic Potential Surface Properties Combined with Partial Least Squares Analysis as New Strategy for the Prediction of the

Activity of Human A3 Adenosine Receptor Antagonists

Moro, Stefano; Bacilieri, Magdalena; Cacciari,

Barbara; Spalluto, Giampiero

CORPORATE SOURCE: Molecular Modeling Section, Dipartimento di Scienze

Farmaceutiche, Università di Padova, Padua, I-35131,

Italy

SOURCE: Journal of Medicinal Chemistry (2005), 48(18),

5698-5704

CODEN: JMCHAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 331472-35-6

RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)

(mol. electrostatic potential surface properties combined with partial least squares anal. for prediction of activity of human A3 adenosine receptor antagonists)

RN 331472-35-6 HCAPLUS

CN Acetic acid, [4-[[[3-phenyl-1,2,4-thiadiazol-5-yl]amino]carbonyl]phenoxy]-(9CI) (CA INDEX NAME)





REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 28 HCAPLUS COPYRIGHT 2006 ACS ON STN

ED Entered STN: 22 Jul 2005

GI



AB The title compds. I [X = a single bond, O, S, SO2 and N; U = an aliphatic linker; Y = O, C, S, NH and a single bond; V = N, O or S; E = CR3A or A (wherein A = carboxy, tetrazole, alkynitrile, carbamate, sulfonamide and acylsulfonamide; R3 = H, alkyl, alkoxy; R4 = H, alkyl, alkoxy, etc. or R3 and R4 are optionally combined to form cycloalkyl); V = (hetero)alkyl, a bond; R1 = H, alkyl, heteroaryl, etc.; R8 = H, alkyl, alkenyl, halo; R9 = H, alkyl, halo, etc.; R10, R11 = H, OH, CN, etc.; R32 = a bond, H, halo, alkyl, etc.] which are modulators of peroxisome proliferator activated receptors (PPARs) and are useful for the treatment of diabetes and other metabolic disorders, were prepared and formulated. E.g., a multi-step synthesis of II, starting from Me glycolate and benzyl bromide, was given. The binding and cotransfection efficacy values for compds. I which are especially useful for modulating a PPAR receptor, are  $\leq 100$  nM and  $\geq 50\%$ , resp.

ACCESSION NUMBER: 2005:638735 HCAPLUS

DOCUMENT NUMBER: 143:153383

TITLE: Preparation of triazole, oxadiazole and thiadiazole derivatives as PPAR modulators for the treatment of diabetes

INVENTOR(S): Mantlo, Nathan Bryan; Navarro, Antonio; Saeed, Ashraf;

Gernert, Douglas Lynn; Ma, Tianwei; Pfeiffer, Lance

Allen

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 175 pp.

CODEN: PIXX02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

L4 ANSWER 9 OF 28 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005065683	A1	20050721	WO 2004-053975	20041221
V:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BU, BV, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPL. INFO.:			US 2003-532320P	P 20031222
			US 2004-586563P	P 20040709
			EP 2004-380158	A 20040721
			EP 2004-380159	A 20040721

OTHER SOURCE(S): MARPAT 143:153383

IT 860261-48-9P 860261-49-0P 860261-56-9P

860261-57-0P 860261-58-1P 860261-70-7P

860261-71-8P 860261-72-9P 860261-73-0P

860261-74-1P 860261-75-2P 860261-76-3P


860261-77-4P 860261-78-5P 860262-51-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazole, oxadiazole and thiadiazole derivs. as PPAR modulators for the treatment of diabetes)

RN 860261-48-9 HCAPLUS

CN Propanoic acid, 2-methyl-2-[4-[[[methyl][5-[4-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl]methyl]amino]methyl]phenoxy]-(9CI) (CA INDEX NAME)




RN 860261-49-0 HCAPLUS


CN Propanoic acid, 2-[4-[[[ethyl][5-[4-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl]methyl]amino]methyl]phenoxy]-2-methyl-(9CI) (CA INDEX NAME)




L4 ANSWER 9 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 860261-56-9 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-5-yl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 860261-57-0 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[methyl[[1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-5-yl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 860261-58-1 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[1-ethyl-3-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-5-yl]methyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 9 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 860261-73-0 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 860261-74-1 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[5-[4-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 860261-75-2 HCAPLUS


L4 ANSWER 9 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 860261-70-7 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[2-propenyl[[5-[4-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 860261-71-8 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[1-methylethyl][5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 860261-72-9 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[1-methylethyl][5-[4-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CN Propanoic acid, 2-methyl-2-[4-[[[methyl][5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 860261-76-3 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[propyl][5-[4-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 860261-77-4 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[2-propenyl][5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




10518347

L4 ANSWER 9 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RN 860261-78-5 HCAPLUS  
 CN Propanoic acid, 2-{4-[[ethyl[[5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl]methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 860262-51-7 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[methyl[[1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-5-yl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




IT 860262-45-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of triazole, oxadiazole and thiadiazole derivs. as PPAR modulators for the treatment of diabetes)  
 RN 860262-45-9 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[2-propenyl[[5-[4-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl]methyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 15 Jun 2005  
 AB 2-Oxo-1,2-ethylenedioxy (2-OED) functionality has been prepared on a soluble MPEG polymer and solid (HM resin and Lanterns) supports as platforms for discovery of drug-like small mols. The functionality is cleaved either by Yb(OTf)<sub>3</sub> or TMSCHN<sub>2</sub> in MeOH, or by various amines to release small mols. synthesized on the platform in good yield. Application of these platforms aiming for discovery of potent agonists for growth hormone secretagogue is reported by using the Ugi four component coupling reaction.  
 ACCESSION NUMBER: 2005:511316 HCAPLUS  
 DOCUMENT NUMBER: 143:173129  
 TITLE: 2-Oxo-1,2-ethylenedioxy group as a linker for solution-, liquid-, and solid-phase syntheses to discover drug-like small molecules  
 AUTHOR(S): Oikawa, Masatoshi Takeda, Yoshiyuki Sasaki, Makoto  
 CORPORATE SOURCE: Laboratory of Biostructural Chemistry, Graduate School of Life Sciences, Tohoku University, Aoba-ku, Sendai, 981-8555, Japan  
 SOURCE: Tetrahedron Letters (2005), 46(27), 4667-4670  
 CODEN: TELEAY; ISSN: 0040-4039  
 PUBLISHER: Elsevier B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 861399-52-2P 861399-54-4P  
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (oxoethylenedioxy group as a linker for solution, liquid and solid-phase syntheses and its use for preparation of growth hormone secretagogue agonist by Ugi four component coupling reaction)  
 RN 861399-52-2 HCAPLUS  
 CN Acetic acid, {4-[2-(cyclohexylamino)-1-[[3-(diethylamino)propyl] [(5-(2-methoxyphenyl)-1H-pyrrol-2-yl)carbonyl]amino]-2-oxoethyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 861399-54-4 HCAPLUS  
 CN Acetic acid, {4-[2-(cyclohexylamino)-1-[[3-(diethylamino)propyl] [(5-(2-methoxyphenyl)-1H-pyrrol-2-yl)carbonyl]amino]-2-oxoethyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 10 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10518347

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 03 Jun 2005  
 GI



AB Title compds. I [p, q = 0-1; R1-2 = H, alkyl; R3-4 = H, alkyl, alkoxy, etc.; R5 = H, alkyl, etc.; R6 = alkyl, halo, alkoxy, Ph, etc.] are prepared For instance, 2-[[[4-[[[5-(4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenyl]oxy]-2-methylpropanoic acid (II) is produced in 7 steps from p-tert-Butylacetophenone, Et oxalate and methylhydrazine. II has EC50 = 0.014  $\mu$ M for PPAR $\alpha$ , 5.447  $\mu$ M for PPAR $\delta$  and 0.007  $\mu$ M for PPAR $\gamma$ . I are useful in the treatment of diabetes, dyslipidemia or syndrome X.

ACCESSION NUMBER: 2005:472128 HCAPLUS

DOCUMENT NUMBER: 143:26597

TITLE: Preparation of substituted pyrazoles as PPAR $\alpha$  and PPAR $\gamma$  agonists for treatment of dyslipidemia

INVENTOR(S): Faucher, Nicolas Eric; Martres, Paul

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 176 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049578	A1	20050602	WO 2004-EP12965	20041115
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:				
		GB 2003-26747		A 20031117
		GB 2003-29462		A 20031219


L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 852814-23-4 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-(2-propenyl)phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 852814-24-5 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-propylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 852814-25-6 HCAPLUS

Page 4308/07/2006


L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

OTHER SOURCE(S): MARPAT 143:26597

IT 852814-21-2P 852814-22-3P 852814-23-4P  
 852814-24-5P 852814-25-6P 852814-26-7P  
 852814-27-8P 852814-28-9P 852814-29-0P  
 852814-30-3P 852814-31-4P 852814-32-5P  
 852814-33-6P 852814-34-7P 852814-37-0P  
 852814-40-5P 852814-41-6P 852814-42-7P  
 852814-43-8P 852814-44-9P 852814-45-0P  
 852814-46-1P 852814-47-2P 852814-48-3P  
 852814-49-4P 852814-50-7P 852814-51-8P  
 852814-52-9P 852814-53-0P 852814-54-1P  
 852814-55-2P 852814-56-3P 852814-57-4P  
 852814-58-5P 852814-59-6P 852814-60-9P  
 852814-61-0P 852814-62-1P 852814-63-2P  
 852814-64-3P 852814-65-4P 852814-66-5P  
 852814-70-1P 852814-73-4P 852814-75-6P  
 852814-77-8P 852814-78-9P 852814-80-3P  
 852814-81-4P 852814-82-5P 852814-83-6P  
 852814-84-7P 852814-85-8P 852814-86-9P  
 852814-87-0P 852814-88-1P 852814-89-2P  
 852814-90-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of substituted pyrazoles as PPAR $\alpha$  and PPAR $\gamma$  agonists for treatment of dyslipidemia)


RN 852814-21-2 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-22-3 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(1-methylethyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-ethyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methoxyphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-26-7 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-ethyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methoxyphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-27-8 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(2-methylpropyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

10518347

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852814-28-9 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(2-methylpropyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 852814-29-0 HCAPLUS  
 CN Propanoic acid, 2-(2-methoxy-4-[[[1-methyl-5-[4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy)-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852814-30-3 HCAPLUS  
 CN Propanoic acid, 2-[2-methoxy-4-[[[1-methyl-3-[4-(1-methylethyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-31-4 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 852814-32-5 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methoxyphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-33-6 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-ethyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-34-7 HCAPLUS

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Propanoic acid, 2-[2-methoxy-4-[[[1-methyl-5-[4-(2-methylpropyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-37-0 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-ethyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-40-5 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

10518347

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852814-41-6 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[[[5-[[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-42-7 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[[[5-[[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852814-43-8 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[[[5-[[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-44-9 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[[[5-[[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852814-45-0 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[[[5-[[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-46-1 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[[[5-[[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852814-47-2 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[[[5-[[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-48-3 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[[[5-[[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

10518347

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852814-49-4 HCAPLUS  
CN Propanoic acid, 2-[4-[[[5-(4-(1,1-dimethylethyl)phenyl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-50-7 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3-(4-(1,1-dimethylethyl)phenyl)-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852814-51-8 HCAPLUS  
CN Propanoic acid, 2-[2-chloro-6-methyl-4-[[[1-methyl-5-[4-(2-methylpropyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-52-9 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3-(1,1'-biphenyl)-3-yl-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 852814-53-0 HCAPLUS  
CN Propanoic acid, 2-[4-[[[5-(4-butylphenyl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-54-1 HCAPLUS  
CN Propanoic acid, 2-[4-[[[5-(4-bromophenyl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-55-2 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-(2'-methyl[1,1'-biphenyl]-4-yl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
biphenyl]-4-yl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 852814-56-3 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-(4-(2-thienyl)phenyl)-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 852814-57-4 HCAPLUS  
CN Propanoic acid, 2-[4-[[[5-(4-(3-furanyl)phenyl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

10518347


L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
y]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-58-5 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[[[1-methyl-5-[[4-(4-pyridinyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852814-61-0 HCAPLUS  
CN Propanoic acid, 2-[[[4-[[[5-(4-butylphenyl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 852814-62-1 HCAPLUS  
CN Propanoic acid, 2-[[[4-[[[5-(4-butylphenyl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-chloro-6-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 852814-59-6 HCAPLUS  
CN Propanoic acid, 2-[[[4-[[[5-(4-(2-furanyl)phenyl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-60-9 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[[[1-methyl-3-(2'-methyl[1,1'-biphenyl]-4-yl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852814-63-2 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[[[1-methyl-3-(4-(4-morpholinyl)phenyl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 852814-64-3 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[[[1-methyl-3-(3-(1-piperidinyl)phenyl)-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

10518347

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852814-65-4 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[3-(1-pyrrolidinyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]- (9CI)  
 (CA INDEX NAME)




RN 852814-66-5 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(1-piperidinyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]- (9CI)  
 (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 852814-73-4 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-propenyl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-75-6 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-methoxyethyl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-77-8 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-oxo-2-phenylethyl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 piperidinyl]phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]- (9CI)  
 (CA INDEX NAME)




RN 852814-70-1 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(1-piperidinyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]- (9CI)  
 (CA INDEX NAME)




L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 852814-78-9 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-(phenylmethyl)-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI)  
 (CA INDEX NAME)




RN 852814-80-3 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-(2-methoxyethyl)-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)






10518347

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RN 852814-81-4 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-82-5 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 852814-83-6 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852814-84-7 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(2-propenyloxy)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 852814-85-8 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(phenylmethoxy)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 852814-86-9 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(phenylmethoxy)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 852814-87-0 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(2-propenyloxy)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 852814-88-1 HCAPLUS


Page 4908/07/2006

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-propenyl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 852814-89-2 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(phenylmethyl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 852814-90-5 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-(2-propenyl)-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)


10518347

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 852814-96-1P 852815-04-4P 852815-08-8P  
 852815-14-6P 852815-15-7P 852815-20-4P  
 852815-21-5P 852815-22-6P 852815-23-7P  
 852815-24-8P 852815-25-9P 852815-26-0P  
 852815-27-1P 852815-28-2P 852815-29-3P  
 852815-30-6P 852815-33-9P 852815-34-0P  
 852815-35-1P 852815-36-2P 852815-37-3P  
 852815-38-4P 852815-39-5P 852815-41-9P  
 852815-42-0P 852815-45-3P 852815-46-4P  
 852815-51-1P 852815-52-2P 852815-53-3P  
 852815-54-4P 852815-55-5P 852815-56-6P  
 852815-57-7P 852815-61-3P 852815-64-6P  
 852815-65-7P 852815-66-8P 852815-67-9P  
 852815-68-0P 852815-69-1P 852815-77-1P  
 852815-85-1P 852815-88-4P 852815-91-9P  
 852815-94-2P 852816-00-3P 852816-02-5P  
 852816-03-6P 852816-04-7P 852816-05-8P  
 852816-06-9P 852816-07-0P 852816-11-6P  
 852816-16-1P 852816-19-4P 852816-21-8P  
 852816-24-1P 852816-27-4P 852816-32-1P  
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of substituted pyrazoles as PPAR $\alpha$  and PPAR $\gamma$   
 agonists for treatment of dyslipidemia)  
 RN 852814-96-1 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-  
 pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl  
 ester (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 852815-14-6 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-ethyl-1H-  
 pyrazol-3-yl]carbonyl]amino]methyl]-2-methoxyphenoxy]-2-methyl-, ethyl  
 ester (9CI) (CA INDEX NAME)




RN 852815-15-7 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-ethyl-1H-  
 pyrazol-3-yl]carbonyl]amino]methyl]-2-methoxyphenoxy]-2-methyl-, ethyl  
 ester (9CI) (CA INDEX NAME)




RN 852815-20-4 HCAPLUS

Page 5008/07/2006

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852815-04-4 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(1-  
 methylethyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-, ethyl  
 ester (9CI) (CA INDEX NAME)




RN 852815-08-8 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-  
 pyrazol-5-yl]carbonyl]amino]methyl]-2-(2-propenyl)phenoxy]-2-methyl-,  
 ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(2-  
 methylpropyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-,  
 ethyl ester (9CI) (CA INDEX NAME)




RN 852815-21-5 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(2-  
 methylpropyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-,  
 ethyl ester (9CI) (CA INDEX NAME)




RN 852815-22-6 HCAPLUS  
 CN Propanoic acid, 2-[2-methoxy-4-[[[1-methyl-5-[4-(1-methylethyl)phenyl]-1H-  
 pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI)  
 (CA INDEX NAME)

10518347

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852815-23-7 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 852815-24-8 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methoxyphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852815-25-9 HCAPLUS  
CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-ethyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 852815-26-0 HCAPLUS  
CN Propanoic acid, 2-[2-methoxy-4-[[[1-methyl-5-[4-(2-methylpropyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 852815-27-1 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-ethyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 852815-28-2 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 852815-29-3 HCAPLUS


Page 5108/07/2006

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 852815-30-6 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 852815-33-9 HCAPLUS  
CN Propanoic acid, 2-[4-[[[5-[4-(bromophenyl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


10518347

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 852815-34-0 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(1-morpholinyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

PAGE 1-A



PAGE 2-A




RN 852815-37-3 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[3-(1-pyrrolidinyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

RN 852815-35-1 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(1-piperidinyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 852815-36-2 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(1-pyrrolidinyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)


PAGE 1-A



PAGE 2-A




RN 852815-38-4 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[5-[1,1'-biphenyl]-4-yl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 852815-39-5 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-(3-bromophenyl)-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

10518347

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852815-41-9 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-(4-bromophenyl)-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI)  
 (CA INDEX NAME)




RN 852815-42-0 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-(1,1'-biphenyl)-4-yl]-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI)  
 (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852815-45-3 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI)  
 (CA INDEX NAME)




RN 852815-46-4 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI)  
 (CA INDEX NAME)


L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 852815-51-1 HCAPLUS  
 CN Propanoic acid, 2-[2-chloro-6-methyl-4-[[[1-methyl-5-[4-(2-methylpropyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI)  
 (CA INDEX NAME)




RN 852815-52-2 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-(1,1'-biphenyl)-3-yl]-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI)  
 (CA INDEX NAME)




RN 852815-53-3 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[5-(4-butylphenyl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI)  
 (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 y]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI)  
 (CA INDEX NAME)



RN 852815-54-4 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(2-thienyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI)  
 (CA INDEX NAME)




PAGE 1-A

PAGE 2-A



10518347

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RN 852815-55-5 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[5-[4-(3-furanyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI)  
 (CA INDEX NAME)



PAGE 1-A




PAGE 2-A

RN 852815-56-6 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(4-pyridinyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 852815-57-7 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[5-[4-(2-furanyl)phenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI)  
 (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 852815-61-3 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[5-[4-(4-butylphenyl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 852815-64-6 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[5-[4-(4-butylphenyl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-chloro-6-methylphenoxy]-2-methyl-, ethyl ester (9CI)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 (9CI) (CA INDEX NAME)



RN 852815-65-7 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(4-morpholinyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 852815-66-8 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[5-[3-bromophenyl]-1-methyl-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI)

10518347

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
(CA INDEX NAME)

RN 852815-67-9 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[3-(1-piperidinyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 852815-77-1 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(1-piperidinyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 852815-68-0 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[3-(1-pyrrolidinyl)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 852815-69-1 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[3-(1-piperidinyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 852815-85-1 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-propenyl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 852815-88-4 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-methoxyethyl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 852815-91-9 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-oxo-2-phenylethyl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 852815-94-2 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(phenylmethyl)-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852816-00-3 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-methoxyethyl)-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 852816-02-5 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852816-03-6 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-(4-morpholinyl)ethyl)-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 852816-04-7 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-(4-morpholinyl)ethyl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 852816-05-8 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-(4-morpholinyl)ethyl)-1H-pyrazol-3-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 852816-06-9 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-(4-morpholinyl)ethyl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




10518347

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852816-07-0 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(2-propenyloxy)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 852816-11-6 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(phenylmethoxy)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 852816-21-8 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(2-propenyl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 852816-24-1 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3-[4-(1,1-dimethylethyl)phenyl]-1-(phenylmethyl)-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 852816-27-4 HCAPLUS

Page 5708/07/2006

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852816-16-1 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(phenylmethoxy)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 852816-19-4 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-5-[4-(2-propenyloxy)phenyl]-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Propanoic acid, 2-[4-[[[5-[4-(1,1-dimethylethyl)phenyl]-1-(2-propenyl)-1H-pyrazol-3-yl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 852816-32-1 HCAPLUS  
CN Propanoic acid, 2-[2-methoxy-4-[[[1-methyl-3-[4-(1-methylethyl)phenyl]-1H-pyrazol-5-yl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10518347

L4 ANSWER 12 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 09 May 2005  
 G1



AB Title compds. I [X = O, S, CH<sub>2</sub>; R<sub>1</sub> = H, alkyl; R<sub>2</sub> = H, alkyl with proviso; R<sub>3</sub> = H, alkyl; R<sub>4</sub>, R<sub>8</sub> = H, alkyl, cycloalkyl, etc.; R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> = H, alkyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, saponification of Et ester II (Z = OEt), afforded acid II (Z = OH) as a light yellow solid. In PPAR $\alpha$  receptor binding assays, 3-examples of compds. I exhibited IC<sub>50</sub> values ranging from 0.013-0.289  $\mu$ mol/l. Compds. I are claimed to be useful for the treatment of diseases modulated by PPAR $\alpha$  and PPAR $\gamma$  agonist.

ACCESSION NUMBER: 2005:394829 HCAPLUS  
 DOCUMENT NUMBER: 142:463605  
 TITLE: Preparation arylomxyacetic acids and related compounds as PPAR $\alpha$  and PPAR $\gamma$  agonists  
 INVENTOR(S): Ackermann, Jean; Aebi, Johannes; Bingselli, Alfred; Grether, Uwe; Hirth, Georges; Kuhn, Bernd; Maerki, Hans-Peter; Meyer, Markus; Mohr, Peter; Wright, Matthew Blake  
 PATENT ASSIGNEE(S): Switz.  
 SOURCE: U.S. Pat. Appl. Publ., 89 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

L4 ANSWER 12 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005096337	A1	20050505	US 2004-978155	20041029
AU 2004291262	A1	20050602	AU 2004-291262	20041028
CA 2543249	AA	20050602	CA 2004-2543249	20041028
WO 2005049573	A1	20050602	WO 2004-EP12217	20041028

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2003-104081 A 20031105  
 EP 2004-100759 A 20040226  
 WO 2004-EP12217 W 20041028

OTHER SOURCE(S): MARPAT 142:463605  
 IT 851506-68-8P 851506-87-1P 851506-88-2P  
 851506-89-3P 851507-10-3P 851507-11-4P  
 851507-16-9P 851507-17-0P 851507-18-1P  
 851507-22-7P 851507-24-9P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation arylomxyacetic acids and related compds. as PPAR $\alpha$  and PPAR $\gamma$  agonists)  
 RN 851506-68-8 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[4-(4-cyclopropyl-2-{4-(trifluoromethyl)phenyl}-5-pyrimidinyl)carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




PAGE 1-A



PAGE 2-A

RN 851506-87-1 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[4-(4-cyclopropyl-2-{4-(trifluoromethyl)phenyl}-5-pyrimidinyl)carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




PAGE 1-A




PAGE 2-A


RN 851506-88-2 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[4-(4-(methoxymethyl)-2-{4-(trifluoromethyl)phenyl}-5-pyrimidinyl)carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 851506-89-3 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[4-(4-(2-methoxyethyl)-2-{4-(trifluoromethyl)phenyl}-5-pyrimidinyl)carbonyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 851507-10-3 HCAPLUS  
CN Propanoic acid, 2-[[[4-(methoxymethyl)-2-[4-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 851507-11-4 HCAPLUS  
CN Propanoic acid, 2-[[[4-(2-methoxyethyl)-2-[4-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 851507-16-9 HCAPLUS  
CN Propanoic acid, 2-[[[4-(cyclopropyl)-2-[4-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 851507-22-7 HCAPLUS  
CN Propanoic acid, 2-[[[4-(3-chloro-4-[[[4-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]amino]methyl]phenoxy]-2-methyl]-2-methoxyethyl]-2-[4-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 851507-24-9 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[4-[[[4-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 851507-17-0 HCAPLUS  
CN Propanoic acid, 2-[[[4-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 851507-18-1 HCAPLUS  
CN Propanoic acid, 2-[[[4-(2-methoxyethyl)-2-[4-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN  
ED Entered STN: 29 Apr 2005  
GI



AB Title compound I and pharmaceutically acceptable salts thereof were prepared for example, acylation of Et 2-[[4-(aminomethyl)phenyl]oxy]-2-methylpropanoate with Et 4-methyl-5-(4-(1-methylethyl)phenyl)-1,3-thiazole-2-carboxylate, e.g., prepared from 2,4-pentanedione in 4 steps, followed by hydrolysis using NaOH afforded compound I. In hPPAR binding assays, the EC50 value of compound I was 0.008 μM. Compd. I is claimed useful for the treatment of hypercholesterolemia, heart failure, etc.

ACCESSION NUMBER: 2005:371233 HCAPLUS  
DOCUMENT NUMBER: 142:411351  
TITLE: Preparation of thiazole-2-carboxamide derivatives as hPPAR agonist  
INVENTOR(S): Gellibert, Francoise Jeanner, Martres, Paul  
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
SOURCE: PCT Int. Appl., 19 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037804	A1	20050428	WO 2004-EP11386	20041007
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZH, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HR, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW				

PRIORITY APPL. INFO.: GB 2003-23702 A 20031009  
OTHER SOURCE(S): CASREACT 142:411351


IT 850534-95-1P  
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of thiazole-2-carboxamide derivs. as hPPAR agonist for treatment of hypercholesterolemia, heart failure, etc.)  
RN 850534-95-1 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-5-(4-(1-methylethyl)phenyl)-2-

10518347

L4 ANSWER 13 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
thiazolyl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



IT 850534-94-OP  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of thiazole-2-carboxamide derivs. as hPPAR agonist for treatment of hypercholesterolemia, heart failure, etc.)  
RN 850534-94-0 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-5-(4-(1-methylethyl)phenyl]-2-thiazolyl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 14 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
CA 2529662 AA 20050210 CA 2004-2529662 20040720  
EP 1656139 A1 20060517 EP 2004-742005 20040720  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR  
NO 2006000815 A 20060220 NO 2006-015 20060220  
PRIORITY APPLN. INFO.: EP 2003-102236 A 20030721  
US 2003-517824P P 20031106  
WO 2004-EP51558 W 20040720

OTHER SOURCE(S): MARPAT 142:219051  
IT 842136-81-6P 842137-31-9P 842137-32-0P  
842137-33-1P 842137-34-2P 842137-35-3P  
842137-36-4P 842137-37-5P 842137-38-6P  
842137-39-7P 842137-40-0P 842137-41-1P  
842137-42-2P 842137-43-3P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate; preparation of aryl dicarboxamides as protein-tyrosine phosphatase (PTP) inhibitors)  
RN 842136-81-6 HCAPLUS  
CN Acetic acid, [4-[[[2-[[[4-(4-pentylphenyl)methyl]amino]carbonyl]phenyl]-4-thiazolyl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



PAGE 1-A



PAGE 1-B

RN 842137-31-9 HCAPLUS  
CN Acetic acid, [4-[[[2-[[[4-(4-pentylphenyl)methyl]amino]carbonyl]phenyl]-4-thiazolyl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN  
ED Entered STN: 11 Feb 2005  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Title compds. I [A = CONHR6 wherein R6 = alkyl, alkenyl, alkynyl, cycloalkyl, etc.; X = aryl, heteroaryl, aryloxy, aryl, etc.; n = 0 or 1; R1 and R2 independently = H or alkyl; R3 = alkyl, alkenyl, alkynyl, alkoxy, etc.; R4 and R5 independently = H, OH, alkyl, carboxy, alkoxy, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as protein-tyrosine phosphatase inhibitors. Thus, e.g., II was prepared via reductive amination of 6-amino-2,2-dimethyl-4H-1,3-benzodioxin-4-one (preparation given) with 4-formylbenzoate and subsequent amidation with 3-cyclopentylpropanoyl chloride, debenzoylation, amidation with 4-phenoxybenzylamine and deprotection. I were evaluated for inhibition of PTP, and in particular PTP1B; e.g., II possessed an IC50 value of 1.0 μM in assays against PTP1B. As PTP inhibitors, I should be useful for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, polycystic ovary syndrome (PCOS).

ACCESSION NUMBER: 2005:120736 HCAPLUS  
DOCUMENT NUMBER: 142:219051  
TITLE: Preparation of aryl dicarboxamides as protein-tyrosine phosphatase inhibitors  
INVENTOR(S): Thomas, Russel J.; Swinnen, Dominique; Pons, Jean-Francois; Bombrun, Agnes  
PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N.V., Neth.  
SOURCE: PCT Int. Appl., 103 pp.  
CODEN: PIXX02  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005011685	A1	20050210	WO 2004-EP51558	20040720
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, MI, MR, NE, SN, TD, TG			
AU 2004260831	A1	20050210	AU 2004-260831	20040720

L4 ANSWER 14 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B


-CF3

RN 842137-32-0 HCAPLUS  
CN Acetic acid, [4-[[[2-[[[4-(4-pentylphenyl)methyl]amino]carbonyl]phenyl]-4-thiazolyl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 842137-33-1 HCAPLUS  
CN Acetic acid, [4-[[[2-[[[4-(4-phenylbutyl)amino]carbonyl]phenyl]-4-thiazolyl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

10518347

L4 ANSWER 14 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 842137-34-2 HCAPLUS  
CN Acetic acid, [4-[[[1-oxo-3-phenylpropyl] [[2-[4-[[[4-phenylbutyl]amino]carbonyl]phenyl]-4-thiazolyl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 842137-35-3 HCAPLUS  
CN Acetic acid, [4-[[[1-oxo-3-phenylpropyl] [[2-[4-[[[4-phenylbutyl]amino]carbonyl]phenyl]-4-thiazolyl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L4 ANSWER 14 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 1-B




RN 842137-39-7 HCAPLUS  
CN Acetic acid, [4-[[[1-oxo-3-phenylpropyl] [[2-[4-[[[4-phenylbutyl]amino]carbonyl]phenyl]-4-thiazolyl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 842137-40-0 HCAPLUS  
CN Acetic acid, [4-[[[1-oxo-3-phenylpropyl] [[2-[4-[[[4-phenylbutyl]amino]carbonyl]phenyl]-4-thiazolyl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 14 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 842137-36-4 HCAPLUS  
CN Acetic acid, [4-[[[1-oxo-3-phenylpropyl] [[2-[4-[[[4-phenylbutyl]amino]carbonyl]phenyl]-4-thiazolyl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 842137-37-5 HCAPLUS  
CN Acetic acid, [4-[[[1-oxo-3-phenylpropyl] [[2-[4-[[[4-phenylbutyl]amino]carbonyl]phenyl]-4-thiazolyl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 842137-38-6 HCAPLUS  
CN Acetic acid, [4-[[[1-oxo-3-phenylpropyl] [[2-[4-[[[4-phenylbutyl]amino]carbonyl]phenyl]-4-thiazolyl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-B



RN 842137-41-1 HCAPLUS  
CN Acetic acid, [4-[[[1-oxo-3-phenylpropyl] [[2-[4-[[[4-phenylbutyl]amino]carbonyl]phenyl]-4-thiazolyl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 842137-42-2 HCAPLUS  
CN Acetic acid, [4-[[[1-oxo-3-phenylpropyl] [[2-[4-[[[4-phenylbutyl]amino]carbonyl]phenyl]-4-thiazolyl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 842137-43-3 HCAPLUS  
CN Acetic acid, [4-[[[1-oxo-3-phenylpropyl] [[2-[4-[[[4-phenylbutyl]amino]carbonyl]phenyl]-4-thiazolyl]methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)


10518347

L4 ANSWER 14 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 842137-63-7P 842137-64-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of aryl dicarboxamides as protein-tyrosine phosphatase (PTP) inhibitors)  
 RN 842137-63-7 HCAPLUS  
 CN Acetic acid, [4-[[[2-[4-[[[4-(4-pentylphenyl)methyl]amino]carbonyl]phenyl]-4-thiazolyl]methyl]amino]methyl]phenoxy]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● HCl

PAGE 1-B




RN 842137-64-8 HCAPLUS  
 CN Acetic acid, [4-[[[2-(E)-1-oxo-3-phenyl-2-propenyl][2-[4-[[[4-(4-pentylphenyl)methyl]amino]carbonyl]phenyl]-4-thiazolyl]methyl]amino]methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 14 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 22 Apr 2004  
 GI



AB The invention includes low mol. weight, non-peptidic, non-peptidomimetic, organic  
 mols. that can act as modulators of mammalian complement C5a receptors, preferably ones that act as high affinity C5a receptor ligands and also such ligands that can act as antagonists or inverse agonists of complement C5a receptors. Preferred compds. of the invention possess some or all of the following properties in that they are: (1) multi-aryl in structure; (2) heteroaryl in structure; (3) a pharmaceutically acceptable oral dose can provide a detectable in vivo effect; (4) comprise fewer than four or preferably no amide bonds, and (5) capable of habiting leukocyte chemotaxis at nanomolar or sub-nanomolar concns. Such compds. include mainly substituted acylimidazoles I [m = 0-2; R1 = H, OH, halo, NH2, etc.; R2 = alkyl, cycloalkyl, haloalkyl, etc.; R3, R32, R5, R6 = H, OH, halo, NH2, etc.; R4 = alkyl, alkenyl, cycloalkyl, etc.; R7 = 0-3 groups selected from halo, NO2, CN, CF3, etc.], and also pyrazoles, amides, etc. Detailed preparation of some of the title compds. was given. E.g., a multi-step synthesis of I (Ar1 = Ph; R1, R31, R32, R7 = H; R2 = Bu; R4 = 3,4-methylenedioxyphenyl) was presented. The invention also includes pharmaceutical composition comprising the title compds. and the use of such compds. in treating a variety of disorders.


ACCESSION NUMBER: 2004:327187 HCAPLUS  
 DOCUMENT NUMBER: 140:321364  
 TITLE: Preparation of substituted imidazoles, pyrazoles and amides as high affinity C5a receptor modulators  
 INVENTOR(S): Thurkauf, Andrew; He, Xiao-shu; Zhao, He; Peterson, John; Zhang, Xiaoyan; Brodbeck, Robbin; Krause, James; Maynard, George; Hutchison, Alan  
 PATENT ASSIGNEE(S): Neurogen Corporation, USA  
 SOURCE: U.S. 592 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6723743	B1	20040420	US 2000-672071	20000928
US 6884815	B1	20050426	US 2003-461311	20030612
PRIORITY APPLN. INFO.:			US 1999-156390P	P 19990928
			US 2000-202749P	P 20000508


Page 6208/07/2006

L4 ANSWER 15 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 US 2000-212499P P 20000616  
 US 2000-221787P P 20000731  
 US 2000-224036P P 20000809  
 US 2000-212449P P 20000616  
 US 2000-672071 A3 20000928

OTHER SOURCE(S): MARPAT 140:321364  
 IT 439571-14-9P 439571-15-0P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of substituted imidazoles, pyrazoles and amides as high affinity C5a receptor modulators)  
 RN 439571-14-9 HCAPLUS  
 CN Acetic acid, [4-[[[1-butyl-2,4-diphenyl-1H-imidazol-5-yl]methyl] (phenylmethyl)amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)





RN 439571-15-0 HCAPLUS  
 CN Acetic acid, [4-[[[1-butyl-2,4-diphenyl-1H-imidazol-5-yl]methyl] (cyclohexylmethyl)amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10518347


L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 02 Jan 2004  
 GI




AB The title compds. [I; R1, R2 = H, alkyl; R3, R4 = H, alkyl, OMe, CF, allyl, halo; n = 0-1; at least of X, Z and Y = O, S, N; R6 = alkyl, CF3, OMe, OCF3, halo; y = 0-5; R7 = H, CF3, alkyl (optionally substituted by phenyl), alkenyl with the proviso that when Z = S, O, R7 = H; R10 = H, alkyl; R5 = H, alkyl, alkoxyalkyl, alkenyl, alkoxy, etc.], useful for treatment of a hPPAR disease or condition such as dyslipidemia, syndrome X, heart failure, hypercholesterolemia, cardiovascular disease, diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia and anorexia nervosa (no biol. data given), were prepared Thus, reacting Et 2-(4-bromomethyl-2,6-dimethylphenoxy)-2-methylpropanoate with (4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl)thiophen-3-ylmethylamine (prepn. given) in the presence of cesium carbonate in 3-methyl-2-butanone followed by hydrolysis afforded II. Pharmaceutical composition comprising

the compound I.  
 ACCESSION NUMBER: 2004:2833 HCAPLUS  
 DOCUMENT NUMBER: 140:77141  
 TITLE: Preparation of 2-[4-(heteroarylaminomethyl)phenoxy]-2-methylpropanoates for treating a hPPAR mediated diseases  
 INVENTOR(S): Dodic, Nerina; Dumaitre, Bernard Andre; Gellibert, Françoise Jeanne; Sierra, Michael Lawrence  
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
 SOURCE: PCT Int. Appl., 89 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 639783-42-9 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl](3-thienylmethyl)amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 639783-44-1 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl]methylamino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000785	A2	20031231	WO 2003-EP6417	20030618
WO 2004000785	A3	20041014		
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003237955	A1	20040106	AU 2003-237955	20030618
EP 1513796	A2	20050316	EP 2003-735642	20030618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005529965	T2	20051006	JP 2004-514763	20030618
US 2005222424	A1	20051006	US 2004-518347	20041217
PRIORITY APPLN. INFO.:				
				GB 2002-14139 A 20020619
				WO 2003-EP6417 W 20030618


OTHER SOURCE(S): MARPAT 140:77141  
 IT 639783-40-7P 639783-42-9P 639783-44-1P  
 639783-46-3P 639783-48-5P 639783-50-9P  
 639783-52-1P 639783-54-3P 639783-55-4P  
 639783-57-6P 639783-59-8P 639783-61-2P  
 639783-63-4P 639783-64-5P 639783-65-6P  
 639783-66-7P 639783-69-0P 639783-70-3P  
 639783-73-6P 639783-78-1P 639783-79-2P  
 639783-80-5P 639783-81-6P 639783-83-8P  
 639783-84-9P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (Preparation of 2-[4-(heteroarylaminomethylphenoxy)]-2-methylpropanoates

for treating a hPPAR mediated diseases)  
 RN 639783-40-7 HCAPLUS  
 CN Propanoic acid, 2-[2,6-dimethyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl](3-thienylmethyl)amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 639783-46-3 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(chlorophenyl)methyl][3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 639783-48-5 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[4-(methoxyphenyl)methyl][1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 639783-50-9 HCAPLUS

CN Propanoic acid, 2-[2,6-dimethyl-4-[[[1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 639783-52-1 HCAPLUS


CN Propanoic acid, 2-[4-[[[(4-fluorophenyl)methyl][1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 639783-54-3 HCAPLUS


CN Propanoic acid, 2-[4-[[[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 639783-59-8 HCAPLUS


CN Propanoic acid, 2-[4-[[[2-chlorophenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 639783-61-2 HCAPLUS


CN Propanoic acid, 2-[4-[[[(4-fluorophenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 639783-55-4 HCAPLUS


CN Propanoic acid, 2-[4-[[[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl]ethylamino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 639783-57-6 HCAPLUS


CN Propanoic acid, 2-[4-[[[(4-methoxyphenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 639783-63-4 HCAPLUS

CN Propanoic acid, 2-methyl-2-[4-[[[1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]methyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 639783-64-5 HCAPLUS

CN Propanoic acid, 2-[2-chloro-4-[[methyl[1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




10518347

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 639783-65-6 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]methyl]propylamino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 639783-66-7 HCAPLUS  
CN Propanoic acid, 2-[2-chloro-4-[[[1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]methyl]-2-propenylamino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 639783-73-6 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]-2-propenylamino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 639783-78-1 HCAPLUS

Page 6508/07/2006

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 639783-69-0 HCAPLUS  
CN Propanoic acid, 2-[2-chloro-4-[[[1-(phenylmethyl)-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-5-yl]methyl]-2-propenylamino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 639783-70-3 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl](2,2,2-trifluoroethyl)amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CN Propanoic acid, 2-[2-chloro-4-[[methyl[[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 639783-79-2 HCAPLUS  
CN Propanoic acid, 2-[2-chloro-4-[[methyl[[4-[4-(trifluoromethyl)phenyl]-2-thiazolyl]methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 639783-80-5 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[4-[[methyl[[1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]methyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 639783-81-6 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[methyl[[1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]methyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 639783-83-8 HCAPLUS  
CN Propanoic acid, 2-[2-chloro-4-[[[1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]methyl]-2-propenylamino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 639783-84-9 HCAPLUS  
CN Propanoic acid, 2-[2-chloro-4-[[methyl[[1-(2-propenyl)-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-5-yl]methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 639783-43-0 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl](3-thienylmethyl)amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 639783-45-2 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl](3-thienylmethyl)amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




IT 639783-41-8P 639783-43-0P 639783-45-2P  
639783-47-4P 639783-49-6P 639783-51-0P  
639783-53-2P 639783-56-5P 639783-58-7P  
639783-60-1P 639783-62-3P 639783-67-8P  
639783-68-9P 639783-71-4P 639783-72-5P  
639783-74-7P 639783-75-8P 639783-76-9P  
639783-77-0P 639783-82-7P 639783-85-0P  
639783-86-1P 639783-87-2P 639783-88-3P  
639783-89-4P 639783-90-7P 639783-91-8P  
639783-92-9P 639783-93-0P 639783-94-1P  
639783-95-2P 639783-96-3P 639783-97-4P  
639783-98-5P 639783-99-6P 639784-00-2P  
639784-01-3P 639784-02-4P 639784-03-5P  
639784-04-6P 639784-05-7P 639784-06-8P  
639784-07-9P 639784-08-0P 639784-09-1P  
639784-10-4P 639784-11-5P 639784-12-6P  
639784-13-7P 639784-14-8P 639784-15-9P  
639784-16-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 2-[4-(heteroarylaminomethylphenoxy)]-2-methylpropanoates for treating a hPPAR mediated diseases)


RN 639783-41-8 HCAPLUS  
CN Propanoic acid, 2-[2,6-dimethyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl](3-thienylmethyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 639783-47-4 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl](3-thienylmethyl)amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 639783-49-6 HCAPLUS  
CN Propanoic acid, 2-[4-[[[3-(4-methoxyphenyl)methyl][1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RN 639783-51-0 HCAPLUS  
 CN Propanoic acid, 2-[4-{[4-(2,6-dimethyl-4-[[[1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 639783-53-2 HCAPLUS  
 CN Propanoic acid, 2-[4-{[4-(4-fluorophenyl)methyl][1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 639783-56-5 HCAPLUS  
 CN Propanoic acid, 2-[4-{[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl]ethylamino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 639783-62-3 HCAPLUS  
 CN Propanoic acid, 2-[4-{[4-(4-fluorophenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 639783-67-8 HCAPLUS  
 CN Propanoic acid, 2-[2-chloro-4-{[methyl[[1-(2-propenyl)-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-5-yl]methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 639783-58-7 HCAPLUS  
 CN Propanoic acid, 2-[4-{[4-(4-methoxyphenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 639783-60-1 HCAPLUS  
 CN Propanoic acid, 2-[4-{[4-(2-chlorophenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2,6-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 639783-68-9 HCAPLUS  
 CN Propanoic acid, 2-[2-chloro-4-{[methyl[[1-(3-methylbutyl)-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-5-yl]methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 639783-71-4 HCAPLUS  
 CN Propanoic acid, 2-[2-chloro-4-{[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 639783-72-5 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[[[4-methyl-2-[[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]-2-propenylamino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 639783-74-7 HCAPLUS  
 CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[[4-methyl-2-[[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 639783-75-8 HCAPLUS  
 CN Propanoic acid, 2-[[4-[[[(3-methoxypropyl)[[4-methyl-2-[[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 639783-76-9 HCAPLUS  
 CN Propanoic acid, 2-(2-chloro-4-[[[4-methyl-2-[[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]phenyl]amino]methyl]phenoxy)-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 639783-77-0 HCAPLUS  
 CN Propanoic acid, 2-[[4-[[[(3-methoxypropyl)[[4-methyl-2-[[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 639783-82-7 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[[2-methyl-4-[[[1-methyl-3-[[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]methyl]propylamino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 639783-85-0 HCAPLUS  
 CN Propanoic acid, 2-[[2-chloro-4-[[[methyl[[1-(3-methylbutyl)-3-[[4-(trifluoromethoxy)phenyl]-1H-pyrazol-5-yl]methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 639783-86-1 HCAPLUS  
 CN Propanoic acid, 2-[2-chloro-4-[[[1-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-5-yl]methyl]-2-propenylamino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 639783-87-2 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl](2,2,2-trifluoroethyl)amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 639783-88-3 HCAPLUS  
 CN Propanoic acid, 2-[2-chloro-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl](2,2,2-trifluoroethyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 639783-89-4 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]-2-propenylamino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 639783-90-7 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl](2,2,2-trifluoroethyl)amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 639783-91-8 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-methoxyethyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 639783-92-9 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[3-methoxypropyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 639783-93-0 HCAPLUS  
 CN Propanoic acid, 2-[2-chloro-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl](phenylmethyl)amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

10518347

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 639783-94-1 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-furanylmethyl)[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 639783-95-2 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl)methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 2-A




RN 639783-98-5 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(4-methoxyphenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 639783-99-6 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[(4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 639783-96-3 HCAPLUS  
 CN Propanoic acid, 2-[2-chloro-4-[[methyl[[4-[4-(trifluoromethyl)phenyl]-2-thiazolyl]methyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 639783-97-4 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(4-methoxyphenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 639784-00-2 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[(4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 639784-01-3 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-furanylmethyl)[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 639784-02-4 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-furanylmethyl)[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)


10518347

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 639784-03-5 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-methoxyphenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 639784-04-6 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-methoxyphenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 639784-06-8 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-methoxyphenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 639784-07-9 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-fluorophenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




Page 7108/07/2006

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
methyl- (9CI) (CA INDEX NAME)

RN 639784-05-7 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(3-methoxyphenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 639784-08-0 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-fluorophenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 639784-09-1 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[(2-chlorophenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

10518347

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 639784-10-4 HCAPLUS

CN Propanoic acid, 2-[4-[[[2-chlorophenyl)methyl][4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 639784-13-7 HCAPLUS

CN Propanoic acid, 2-[4-[[[2-fluorophenyl)methyl][1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 639784-14-8 HCAPLUS


CN Propanoic acid, 2-[4-[[[2-fluorophenyl)methyl][1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

639784-11-5 HCAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[methyl[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 639784-12-6 HCAPLUS


CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[methyl[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 639784-15-9 HCAPLUS

CN Propanoic acid, 2-[4-[[[2-methoxyphenyl)methyl][1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]amino]methyl]-2-methylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 639784-16-0 HCAPLUS


CN Propanoic acid, 2-[4-[[[2-methoxyphenyl)methyl][1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]amino]methyl]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



IT 639784-86-4P



L4 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[4-methyl-2-[4-  
 (trifluoromethyl)phenyl]-5-thiazolyl]amino]methyl]phenoxy]-, ethyl ester  
 (9CI) (CA INDEX NAME)




PAGE 1-A



PAGE 2-A

L4 ANSWER 17 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 02 Jan 2004  
 GI



II

AB Title compds. I [wherein R1 and R2 = independently H or alkyl; X = a bond, CH2, or O; R3 and R4 = independently H, alkyl, OCH3, CF3, allyl, or halo; X1 = CH2, SO2, or CO; R5 = alkenyl, alkanyl, alkylsulfonyl, or (un)substituted alkyl(phenyl); R6 = (un)substituted Ph or 6-membered heteroaryl; or pharmaceutically acceptable salts, solvates, or hydrolyzable esters thereof] were prepared as human peroxisome proliferator activated receptor (hPPAR) activators. For example, coupling of Et 2-methyl-2-[2-methyl-4-[[[4-(trifluoromethyl)benzyl]amino]methyl]phenoxy]propanoate with 2-bromo-6-[4-(trifluoromethyl)phenyl]pyridine in the presence of Pd(OAc)2, (R)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, and cesium carbonate in toluene gave the tertiary amine. Saponification with NaOH in THF provided the acid II. Compds. of the invention showed at least 50% activation of hPPAR $\alpha$  relative to the pos. control at concns. of 10<sup>-7</sup> M or less. Thus, I and their pharmaceutical compns. are useful for the treatment of hPPAR mediated conditions, such as dyslipidemia, syndrome X, heart failure, hypercholesterolemia, cardiovascular disease, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia, or anorexia nervosa [no data].

ACCESSION NUMBER: 2004:2818 HCAPLUS  
 DOCUMENT NUMBER: 140:59406  
 TITLE: Preparation of [[[(hetero)arylamino]methyl]phenoxy]acetic acid derivatives as hPPAR activators for treatment of cardiovascular disease and related disorders  
 INVENTOR(S): Beswick, Paul John; Harling, John David; Kleanthous, Savvas; Patel, Vipulkumar; Kanibhai, Simpson, Juliet  
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
 SOURCE: PCT Int. Appl., 98 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent



L4 ANSWER 17 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000762	A2	20031231	WO 2003-EP6416	20030618
WO 2004000762	A3	20041014		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MW, MX, MY, NZ, NI, NO, NZ, OH, PE, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TH, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2489359	AA	20031231	CA 2003-2489359	20030618
AU 2003245963	A1	20040106	AU 2003-245963	20030618
EP 1513795	A2	20050316	EP 2003-738057	20030618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LT, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011935	A	20050322	BR 2003-11935	20030618
JP 2005534673	T2	20051117	JP 2004-514762	20030618
NO 2004005327	A	20050310	NO 2004-5327	20041203
US 2006074111	A1	20060406	US 2004-518778	20041217
PRIORITY APPL. INFO.: GB 2002-14254 A 20020620 WO 2003-EP6416 W 20030618				



OTHER SOURCE(S): MARPAT 140:59406  
 IT 637353-48-1P, [4-[[[Butyl[4-[[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-49-2P, [4-[[[Butyl[4-[[4-chlorophenyl]pyrimidin-2-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-50-5P, [4-[[[2-Methoxyethyl]-4-[[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-51-6P, [4-[[[4-(4-chlorophenyl)pyrimidin-2-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-52-7P, [2-Methyl-4-[[[propyl[4-[[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]amino]methyl]phenoxy]acetic acid 637353-53-8P, [4-[[[Butyl[6-[[4-(trifluoromethyl)phenyl]pyrazin-2-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-54-9P, [4-[[[Butyl[6-[[4-(methylphenyl)pyrazin-2-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-55-0P, [4-[[[2-Methoxyethyl]-6-[[4-(trifluoromethyl)phenyl]pyrazin-2-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-70-9P, [4-[[[Butyl[5-methyl-6-[[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-71-0P, [4-[[[Butyl[6-[[4-methoxyphenyl]-5-methylpyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-72-1P, [4-[[[Butyl[5-methyl-6-[[4-methylphenyl]pyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-73-2P, [4-[[[Butyl[6-[[4-chlorophenyl]-5-methylpyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-74-3P, [4-[[[Butyl[6-[[4-chlorophenyl]pyrazin-2-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-75-4P, [4-[[[6-[[4-Chlorophenyl]pyrazin-2-yl]-2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-76-5P, [2-Methyl-4-[[[propyl[6-[[4-(trifluoromethyl)phenyl]pyrazin-2-yl]amino]methyl]phenoxy]acetic acid 637353-77-6P, [2-Methyl-4-[[[5-methyl-6-[[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]methyl]phenoxy]acetic acid 637353-78-7P, [4-[[[6-[[4-Chlorophenyl]pyrimidin-2-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-79-8P, [2-Methyl-4-[[[5-methyl-6-[[4-(methylphenyl)pyrimidin-4-yl]amino]methyl]phenoxy]acetic acid 637353-80-1P, [2-Methyl-4-[[[5-methyl-6-[[4-(methoxyphenyl)pyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-81-2P, [4-[[[Butyl[6-[[4-(trifluoromethyl)phenyl]pyrazin-2-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-82-3P, [2-Ethyl-4-[[[2-methylphenoxy]acetic acid 637353-83-4P, [4-[[[Butyl[5-methyl-6-[[4-(methylphenyl)pyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-85-6P, [4-[[[Butyl[6-[[4-chlorophenyl]-5-methylpyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-86-7P, [4-[[[Butyl[5-methyl-6-[[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetic acid 637353-87-8P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-88-9P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-89-0P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-90-1P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-91-2P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-92-3P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-93-4P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-94-5P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-95-6P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-96-7P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-97-8P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-98-9P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-99-0P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-100-1P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-101-2P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-102-3P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-103-4P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-104-5P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-105-6P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-106-7P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-107-8P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-108-9P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-109-0P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-110-1P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-111-2P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-112-3P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-113-4P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-114-5P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-115-6P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-116-7P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-117-8P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-118-9P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-119-0P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-120-1P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-121-2P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-122-3P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-123-4P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-124-5P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-125-6P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-126-7P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-127-8P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-128-9P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-129-0P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-130-1P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-131-2P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-132-3P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-133-4P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-134-5P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-135-6P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-136-7P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-137-8P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-138-9P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-139-0P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-140-1P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-141-2P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-142-3P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-143-4P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-144-5P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-145-6P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-146-7P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-147-8P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-148-9P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-149-0P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-150-1P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-151-2P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-152-3P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-153-4P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-154-5P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-155-6P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-156-7P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-157-8P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-158-9P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-159-0P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-160-1P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-161-2P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-162-3P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-163-4P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-164-5P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-165-6P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-166-7P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-167-8P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-168-9P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-169-0P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-170-1P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-171-2P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-172-3P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-173-4P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-174-5P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-175-6P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-176-7P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-177-8P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-178-9P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-179-0P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-180-1P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-181-2P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-182-3P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-183-4P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-184-5P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-185-6P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-186-7P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-187-8P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-188-9P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-189-0P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-190-1P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-191-2P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-192-3P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-193-4P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-194-5P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-195-6P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-196-7P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-197-8P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-198-9P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-199-0P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-200-1P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-201-2P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-202-3P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-203-4P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-204-5P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-205-6P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-206-7P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-207-8P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-208-9P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-209-0P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-210-1P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-211-2P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-212-3P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-213-4P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-214-5P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-215-6P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-216-7P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-217-8P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-218-9P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-219-0P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-220-1P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-221-2P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-222-3P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-223-4P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-224-5P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-225-6P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-226-7P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-227-8P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-228-9P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-229-0P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-230-1P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-231-2P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-232-3P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-233-4P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-234-5P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-235-6P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-236-7P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-237-8P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-238-9P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-239-0P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-240-1P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-241-2P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-242-3P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-243-4P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-244-5P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-245-6P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-246-7P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-247-8P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-248-9P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-249-0P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-250-1P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-251-2P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-252-3P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-253-4P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-254-5P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-255-6P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-256-7P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-257-8P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-258-9P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-259-0P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-260-1P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methylphenoxy]acetic acid 637353-261-2P, [2-Ethyl-4-[[[2-(methoxyethyl)]amino]methyl]-2-methyl

10518347


L4 ANSWER 17 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 637353-51-6 HCAPLUS  
CN Acetic acid, [4-[[[4-(4-chlorophenyl)-2-pyrimidinyl] (2-methoxyethyl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 637353-52-7 HCAPLUS  
CN Acetic acid, [2-methyl-4-[[[propyl[4-(4-(trifluoromethyl)phenyl)-2-pyrimidinyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 637353-53-8 HCAPLUS  
CN Acetic acid, [4-[[[butyl[6-(4-(trifluoromethyl)phenyl)pyrazinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 637353-70-9 HCAPLUS  
CN Acetic acid, [4-[[[butyl[5-methyl-6-(4-(trifluoromethyl)phenyl)-4-pyrimidinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 637353-71-0 HCAPLUS  
CN Acetic acid, [4-[[[butyl[6-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-72-1 HCAPLUS  
CN Acetic acid, [4-[[[butyl[5-methyl-6-(4-methylphenyl)-4-pyrimidinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 637353-73-2 HCAPLUS  
CN Acetic acid, [4-[[[butyl[6-(4-chlorophenyl)-5-methyl-4-pyrimidinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 637353-74-3 HCAPLUS  
CN Acetic acid, [4-[[[butyl[6-(4-chlorophenyl)pyrazinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 637353-54-9 HCAPLUS  
CN Acetic acid, [4-[[[butyl[6-(4-methylphenyl)pyrazinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)





RN 637353-55-0 HCAPLUS  
CN Acetic acid, [4-[[[2-methoxyethyl][6-(4-(trifluoromethyl)phenyl)pyrazinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




L4 ANSWER 17 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 637353-75-4 HCAPLUS  
CN Acetic acid, [4-[[[6-(4-chlorophenyl)pyrazinyl] (2-methoxyethyl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 637353-76-5 HCAPLUS  
CN Acetic acid, [2-methyl-4-[[[propyl[6-(4-(trifluoromethyl)phenyl)pyrazinyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 637353-77-6 HCAPLUS  
CN Acetic acid, [2-methyl-4-[[[5-methyl-6-(4-(trifluoromethyl)phenyl)-4-pyrimidinyl]propylamino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 637353-78-7 HCAPLUS  
CN Acetic acid, [4-[[[6-(4-chlorophenyl)-5-methyl-4-pyrimidinyl]propylamino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-79-8 HCAPLUS  
CN Acetic acid, [2-methyl-4-[[[5-methyl-6-(4-methylphenyl)-4-pyrimidinyl]propylamino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 637353-80-1 HCAPLUS  
CN Acetic acid, [4-[[[6-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]propylamino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 637353-81-2 HCAPLUS  
CN Acetic acid, [4-[[[butyl[6-(4-(trifluoromethyl)phenyl)pyrazinyl]amino]methyl]-2-ethylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-85-6 HCAPLUS  
CN Acetic acid, [4-[[[butyl[6-(4-chlorophenyl)-5-methyl-4-pyrimidinyl]amino]methyl]-2-ethylphenoxy]- (9CI) (CA INDEX NAME)




RN 637353-86-7 HCAPLUS  
CN Acetic acid, [4-[[[butyl[5-methyl-6-(4-(trifluoromethyl)phenyl)-4-pyrimidinyl]amino]methyl]-2-ethylphenoxy]- (9CI) (CA INDEX NAME)





RN 637353-87-8 HCAPLUS  
CN Acetic acid, [2-ethyl-4-[[[2-methoxyethyl][4-(4-(trifluoromethyl)phenyl)-2-pyrimidinyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




IT 637352-79-5P, Ethyl 2-[4-[[[butyl[4-(4-(trifluoromethyl)phenyl)pyrimidin-2-yl]amino]methyl]-2-methylphenoxy]acetate 637352-80-8P, Ethyl 2-[4-[[[butyl[4-(4-chlorophenyl)pyrimidin-2-yl]amino]methyl]-2-methylphenoxy]acetate 637352-81-9P, Ethyl 2-[4-[[[2-methoxyethyl][4-(4-(trifluoromethyl)phenyl)pyrimidin-2-yl]amino]methyl]-2-methylphenoxy]acetate 637352-82-0P, Ethyl 2-[4-[[[4-(4-chlorophenyl)pyrimidin-2-yl]amino]methyl]-2-methylphenoxy]acetate 637352-83-1P, Ethyl 2-[2-methyl-4-[[[propyl[4-(4-(trifluoromethyl)phenyl)pyrimidin-2-yl]amino]methyl]phenoxy]acetate 637352-88-6P, Ethyl 2-[4-[[[butyl[6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl]amino]methyl]-2-



RN 637353-82-3 HCAPLUS  
CN Acetic acid, [2-ethyl-4-[[[2-methoxyethyl][6-(4-(trifluoromethyl)phenyl)pyrazinyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 637353-83-4 HCAPLUS  
CN Acetic acid, [4-[[[butyl[5-methyl-6-(4-methylphenyl)-4-pyrimidinyl]amino]methyl]-2-ethylphenoxy]- (9CI) (CA INDEX NAME)



methylphenoxy]acetate 637352-89-7P, Ethyl 2-[4-[[[butyl[6-(4-methylphenyl)pyrazin-2-yl]amino]methyl]-2-methylphenoxy]acetate 637352-90-0P, Ethyl 2-[4-[[[2-methoxyethyl][6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl]amino]methyl]-2-methylphenoxy]acetate 637353-01-6P, Ethyl 2-[4-[[[butyl[5-methyl-6-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetate 637353-02-7P, Ethyl 2-[4-[[[butyl[6-(4-methoxyphenyl)-5-methylpyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetate 637353-03-8P, Ethyl 2-[4-[[[butyl[6-(4-chlorophenyl)-5-methylpyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetate 637353-04-9P, Ethyl 2-[4-[[[butyl[5-methyl-6-(4-methylphenyl)pyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetate 637353-11-6P, Ethyl 2-[4-[[[butyl[6-(4-chlorophenyl)pyrazin-2-yl]amino]methyl]-2-methylphenoxy]acetate 637353-12-9P, Ethyl 2-[4-[[[6-(4-chlorophenyl)pyrazin-2-yl][2-(methyloxy)ethyl]amino]methyl]-2-methylphenoxy]acetate 637353-13-0P, Ethyl 2-[2-methyl-4-[[[propyl[6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl]amino]methyl]phenoxy]acetate 637353-14-1P, Ethyl 2-[2-methyl-4-[[[5-methyl-6-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl]amino]methyl]phenoxy]acetate 637353-15-2P, Ethyl 2-[4-[[[6-(4-chlorophenyl)-5-methylpyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetate 637353-16-3P, Ethyl 2-[2-methyl-4-[[[5-methyl-6-(4-methylphenyl)pyrimidin-4-yl]amino]methyl]phenoxy]acetate 637353-17-4P, Ethyl 2-[2-methyl-4-[[[5-methyl-6-(4-methyloxy)phenyl]pyrimidin-4-yl]amino]methyl]phenoxy]acetate 637353-23-2P, Ethyl 2-[4-[[[butyl[6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl]amino]methyl]-2-ethylphenoxy]acetate 637353-24-3P, Ethyl 2-[2-ethyl-4-[[[2-methoxyethyl][6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl]amino]methyl]phenoxy]acetate 637353-25-4P, Ethyl 2-[4-[[[butyl[5-methyl-6-(4-methylphenyl)pyrimidin-4-yl]amino]methyl]-2-ethylphenoxy]acetate 637353-28-7P, Ethyl 2-[4-[[[butyl[6-(4-chlorophenyl)-5-methylpyrimidin-4-yl]amino]methyl]-2-ethylphenoxy]acetate 637353-29-8P, Ethyl 2-[4-[[[butyl[5-methyl-6-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl]amino]methyl]-2-ethylphenoxy]acetate 637353-30-1P, Ethyl 2-[2-ethyl-4-[[[2-(methyloxy)ethyl][4-(4-(trifluoromethyl)phenyl)pyrimidin-2-yl]amino]methyl]phenoxy]acetate


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(Intermediate; prepn. of [[[hetero]arylamino]methyl]phenoxy]acetic acid derivs. as hPPAR activators for treatment of cardiovascular disease and related disorders)

RN 637352-79-5 HCAPLUS  
CN Acetic acid, [4-[[[butyl[4-(4-(trifluoromethyl)phenyl)-2-pyrimidinyl]amino]methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637352-80-8 HCAPLUS  
CN Acetic acid, [4-[[[butyl[4-(4-chlorophenyl)-2-pyrimidinyl]amino]methyl]-2-


L4 ANSWER 17 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 637352-81-9 HCAPLUS  
CN Acetic acid, [4-[[[(2-methoxyethyl)[4-(4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino)methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637352-82-0 HCAPLUS  
CN Acetic acid, [4-[[[4-(4-chlorophenyl)-2-pyrimidinyl](2-methoxyethyl)amino)methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637352-83-1 HCAPLUS  
CN Acetic acid, [2-methyl-4-[[propyl[4-(4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino)methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 17 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 637353-01-6 HCAPLUS  
CN Acetic acid, [4-[[[butyl[5-methyl-6-(4-(trifluoromethyl)phenyl)-4-pyrimidinyl]amino)methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637353-02-7 HCAPLUS  
CN Acetic acid, [4-[[[butyl[6-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]amino)methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637353-03-8 HCAPLUS  
CN Acetic acid, [4-[[[butyl[6-(4-chlorophenyl)-5-methyl-4-pyrimidinyl]amino)methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 17 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 637352-88-6 HCAPLUS  
CN Acetic acid, [4-[[[butyl[6-(4-(trifluoromethyl)phenyl)pyrazinyl]amino)methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637352-89-7 HCAPLUS  
CN Acetic acid, [4-[[[butyl[6-(4-methylphenyl)pyrazinyl]amino)methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637352-90-0 HCAPLUS  
CN Acetic acid, [4-[[[(2-methoxyethyl)[6-(4-(trifluoromethyl)phenyl)pyrazinyl]amino)methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 17 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 637353-04-9 HCAPLUS  
CN Acetic acid, [4-[[[butyl[5-methyl-6-(4-methylphenyl)-4-pyrimidinyl]amino)methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)





RN 637353-11-8 HCAPLUS  
CN Acetic acid, [4-[[[butyl[6-(4-chlorophenyl)pyrazinyl]amino)methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637353-12-9 HCAPLUS  
CN Acetic acid, [4-[[[6-(4-chlorophenyl)pyrazinyl](2-methoxyethyl)amino)methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 17 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 637353-13-0 HCAPLUS  
 CN Acetic acid, [2-methyl-4-[[propyl[6-[4-(trifluoromethyl)phenyl]pyrazinyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637353-14-1 HCAPLUS  
 CN Acetic acid, [2-methyl-4-[[[5-methyl-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]propylamino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)





RN 637353-15-2 HCAPLUS


L4 ANSWER 17 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 637353-24-3 HCAPLUS  
 CN Acetic acid, [2-ethyl-4-[[[2-methoxyethyl][6-[4-(trifluoromethyl)phenyl]pyrazinyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637353-25-4 HCAPLUS  
 CN Acetic acid, [4-[[[butyl[5-methyl-6-(4-methylphenyl)-4-pyrimidinyl]amino]methyl]-2-ethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637353-28-7 HCAPLUS  
 CN Acetic acid, [4-[[[butyl[6-(4-chlorophenyl)-5-methyl-4-pyrimidinyl]amino]methyl]-2-ethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Page 7708/07/2006


L4 ANSWER 17 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 CN Acetic acid, [4-[[[6-(4-chlorophenyl)-5-methyl-4-pyrimidinyl]propylamino]methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 637353-16-3 HCAPLUS  
 CN Acetic acid, [2-methyl-4-[[[5-methyl-6-(4-methylphenyl)-4-pyrimidinyl]propylamino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637353-17-4 HCAPLUS  
 CN Acetic acid, [4-[[[6-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]propylamino]methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637353-23-2 HCAPLUS  
 CN Acetic acid, [4-[[[butyl[6-[4-(trifluoromethyl)phenyl]pyrazinyl]amino]methyl]-2-ethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 637353-29-8 HCAPLUS  
 CN Acetic acid, [4-[[[butyl[5-methyl-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]-2-ethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 637353-30-1 HCAPLUS  
 CN Acetic acid, [2-ethyl-4-[[[2-methoxyethyl][4-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)






AB 2-Acylaminothiazole derivs. or pharmacaceutically acceptable salts thereof (1: Ar1 = each (un)substituted aryl, monocyclic aromatic heterocyclyl, or bicyclic condensed heterocyclyl; R1 = each (un)substituted aryl or monocyclic aromatic heterocyclyl; R2 = Q, Q1, R24R25n; wherein n, m = an integer of 1-3; when n or m is an integer of 22, CR20R21 and CR22R23 may represent a different group such as O, S, NR26, CR27R28; E, G, J, L = H, CR29R30, R26-R28, CR29, CR30, CR31, CR32, CR33, CR34, CR35, CR36, CR37, CR38, CR39, CR40, CR41, CR42, CR43, CR44, CR45, CR46, CR47, CR48, CR49, CR50, CR51, CR52, CR53, CR54, CR55, CR56, CR57, CR58, CR59, CR60, CR61, CR62, CR63, CR64, CR65, CR66, CR67, CR68, CR69, CR70, CR71, CR72, CR73, CR74, CR75, CR76, CR77, CR78, CR79, CR80, CR81, CR82, CR83, CR84, CR85, CR86, CR87, CR88, CR89, CR90, CR91, CR92, CR93, CR94, CR95, CR96, CR97, CR98, CR99, CR100, CR101, CR102, CR103, CR104, CR105, CR106, CR107, CR108, CR109, CR110, CR111, CR112, CR113, CR114, CR115, CR116, CR117, CR118, CR119, CR120, CR121, CR122, CR123, CR124, CR125, CR126, CR127, CR128, CR129, CR130, CR131, CR132, CR133, CR134, CR135, CR136, CR137, CR138, CR139, CR140, CR141, CR142, CR143, CR144, CR145, CR146, CR147, CR148, CR149, CR150, CR151, CR152, CR153, CR154, CR155, CR156, CR157, CR158, CR159, CR160, CR161, CR162, CR163, CR164, CR165, CR166, CR167, CR168, CR169, CR170, CR171, CR172, CR173, CR174, CR175, CR176, CR177, CR178, CR179, CR180, CR181, CR182, CR183, CR184, CR185, CR186, CR187, CR188, CR189, CR190, CR191, CR192, CR193, CR194, CR195, CR196, CR197, CR198, CR199, CR200, CR201, CR202, CR203, CR204, CR205, CR206, CR207, CR208, CR209, CR210, CR211, CR212, CR213, CR214, CR215, CR216, CR217, CR218, CR219, CR220, CR221, CR222, CR223, CR224, CR225, CR226, CR227, CR228, CR229, CR230, CR231, CR232, CR233, CR234, CR235, CR236, CR237, CR238, CR239, CR240, CR241, CR242, CR243, CR244, CR245, CR246, CR247, CR248, CR249, CR250, CR251, CR252, CR253, CR254, CR255, CR256, CR257, CR258, CR259, CR260, CR261, CR262, CR263, CR264, CR265, CR266, CR267, CR268, CR269, CR270, CR271, CR272, CR273, CR274, CR275, CR276, CR277, CR278, CR279, CR280, CR281, CR282, CR283, CR284, CR285, CR286, CR287, CR288, CR289, CR290, CR291, CR292, CR293, CR294, CR295, CR296, CR297, CR298, CR299, CR300, CR301, CR302, CR303, CR304, CR305, CR306, CR307, CR308, CR309, CR310, CR311, CR312, CR313, CR314, CR315, CR316, CR317, CR318, CR319, CR320, CR321, CR322, CR323, CR324, CR325, CR326, CR327, CR328, CR329, CR330, CR331, CR332, CR333, CR334, CR335, CR336, CR337, CR338, CR339, CR340, CR341, CR342, CR343, CR344, CR345, CR346, CR347, CR348, CR349, CR350, CR351, CR352, CR353, CR354, CR355, CR356, CR357, CR358, CR359, CR360, CR361, CR362, CR363, CR364, CR365, CR366, CR367, CR368, CR369, CR370, CR371, CR372, CR373, CR374, CR375, CR376, CR377, CR378, CR379, CR380, CR381, CR382, CR383, CR384, CR385, CR386, CR387, CR388, CR389, CR390, CR391, CR392, CR393, CR394, CR395, CR396, CR397, CR398, CR399, CR400, CR401, CR402, CR403, CR404, CR405, CR406, CR407, CR408, CR409, CR410, CR411, CR412, CR413, CR414, CR415, CR416, CR417, CR418, CR419, CR420, CR421, CR422, CR423, CR424, CR425, CR426, CR427, CR428, CR429, CR430, CR431, CR432, CR433, CR434, CR435, CR436, CR437, CR438, CR439, CR440, CR441, CR442, CR443, CR444, CR445, CR446, CR447, CR448, CR449, CR450, CR451, CR452, CR453, CR454, CR455, CR456, CR457, CR458, CR459, CR460, CR461, CR462, CR463, CR464, CR465, CR466, CR467, CR468, CR469, CR470, CR471, CR472, CR473, CR474, CR475, CR476, CR477, CR478, CR479, CR480, CR481, CR482, CR483, CR484, CR485, CR486, CR487, CR488, CR489, CR490, CR491, CR492, CR493, CR494, CR495, CR496, CR497, CR498, CR499, CR500, CR501, CR502, CR503, CR504, CR505, CR506, CR507, CR508, CR509, CR510, CR511, CR512, CR513, CR514, CR515, CR516, CR517, CR518, CR519, CR520, CR521, CR522, CR523, CR524, CR525, CR526, CR527, CR528, CR529, CR530, CR531, CR532, CR533, CR534, CR535, CR536, CR537, CR538, CR539, CR540, CR541, CR542, CR543, CR544, CR545, CR546, CR547, CR548, CR549, CR550, CR551, CR552, CR553, CR554, CR555, CR556, CR557, CR558, CR559, CR560, CR561, CR562, CR563, CR564, CR565, CR566, CR567, CR568, CR569, CR570, CR571, CR572, CR573, CR574, CR575, CR576, CR577, CR578, CR579, CR580, CR581, CR582, CR583, CR584, CR585, CR586, CR587, CR588, CR589, CR590, CR591, CR592, CR593, CR594, CR595, CR596, CR597, CR598, CR599, CR600, CR601, CR602, CR603, CR604, CR605, CR606, CR607, CR608, CR609, CR610, CR611, CR612, CR613, CR614, CR615, CR616, CR617, CR618, CR619, CR620, CR621, CR622, CR623, CR624, CR625, CR626, CR627, CR628, CR629, CR630, CR631, CR632, CR633, CR634, CR635, CR636, CR637, CR638, CR639, CR640, CR641, CR642, CR643, CR644, CR645, CR646, CR647, CR648, CR649, CR650, CR651, CR652, CR653, CR654, CR655, CR656, CR657, CR658, CR659, CR660, CR661, CR662, CR663, CR664, CR665, CR666, CR667, CR668, CR669, CR670, CR671, CR672, CR673, CR674, CR675, CR676, CR677, CR678, CR679, CR680, CR681, CR682, CR683, CR684, CR685, CR686, CR687, CR688, CR689, CR690, CR691, CR692, CR693, CR694, CR695, CR696, CR697, CR698, CR699, CR700, CR701, CR702, CR703, CR704, CR705, CR706, CR707, CR708, CR709, CR710, CR711, CR712, CR713, CR714, CR715, CR716, CR717, CR718, CR719, CR720, CR721, CR722, CR723, CR724, CR725, CR726, CR727, CR728, CR729, CR730, CR731, CR732, CR733, CR734, CR735, CR736, CR737, CR738, CR739, CR740, CR741, CR742, CR743, CR744, CR745, CR746, CR747, CR748, CR749, CR750, CR751, CR752, CR753, CR754, CR755, CR756, CR757, CR758, CR759, CR760, CR761, CR762, CR763, CR764, CR765, CR766, CR767, CR768, CR769, CR770, CR771, CR772, CR773, CR774, CR775, CR776, CR777, CR778, CR779, CR780, CR781, CR782, CR783, CR784, CR785, CR786, CR787, CR788, CR789, CR790, CR791, CR792, CR793, CR794, CR795, CR796, CR797, CR798, CR799, CR800, CR801, CR802, CR803, CR804, CR805, CR806, CR807, CR808, CR809, CR810, CR811, CR812, CR813, CR814, CR815, CR816, CR817, CR818, CR819, CR820, CR821, CR822, CR823, CR824, CR825, CR8


ACCESSION NUMBER: 2003:591177 HCAPLWS  
DOCUMENT NUMBER: 139:149652  
TITLE: Preparation of 2-acylaminothiazole derivatives or salts thereof as c-Mpl receptor ligands  
INVENTOR(S): Sugawara, Keizo; Watanuki, Susumu; Koga, Yuji; Nagata, Hiroshi; Obitsu, Kazuyoshi; Wakayama, Ryutarō; Hirayama, Fukuishi; Suzuki, Ken-ichi  
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

L4 ANSWER 18 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●<sub>x</sub> HCl

RN 570404-71-6 HCAPLUS  
CN Acetic acid, [2-chloro-4-[[[5-(4-cyclohexyl-1-piperazinyl)-4-(4-fluorophenyl)-2-thiazolyl]amino]carbonyl]phenoxy]-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)



●x HC-1



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 28 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)  
SOURCE: PCT Int. Appl., 110 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062233		20030731	WO 2003-IP270	20030115
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, IL, IN, IS, JP, KE, KG, KR, KZ, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, OZ, PA, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, KG, KP, KR, KZ, MA, MG, MK, MW, MX, MY, NG, NI, NO, NZ, OM, PG, PH, PK, PR, PT, RW, SC, SD, SE, SG, SK, SL, SN, TH, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	AG, AL, AM, AN, AR, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, GW, HA, HB, HC, HD, HE, HF, HG, HH, HI, HM, HN, HP, HR, HU, ID, IG, IL, IN, IP, IR, IS, IT, IZ, JA, JC, JE, JG, JK, JL, JM, JN, JO, JP, KE, KG, KH, KI, KM, KN, KP, KR, KS, KU, KZ, KY, LA, LB, LC, LD, LE, LG, LH, LI, LJ, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MH, MI, MJ, MK, ML, MM, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NC, ND, NE, NG, NH, NI, NL, NO, NP, NR, NT, NU, NZ, OZ, PA, PE, PG, PH, PK, PL, PM, PN, PR, PS, PT, PU, PY, QA, QG, QH, QJ, QK, QL, QM, QN, QP, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SR, SS, ST, SU, SV, SW, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TR, TS, TT, TV, TW, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UU, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YY, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ			
CA 2472711	AA	20030731	CA 2003-2472711	20030115
EP 1466912	A	20040103	EP 2003-700571	20030115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EG, HU, SK				
CN 1639157	A	20050713	CN 2003-804457	20030115
CN 2005153977	A	20050714	US 2003-009694	20030115
PRIORITY APPLN. INFO.:			JP 2003-10413	A 20030115
			JP 2002-10447	A 20020118
			WO 2003-IP270	W 20030115

OTHER SOURCE(S): MARPAT 139:149652  
IT 570404-70-5P 570404-71-6P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(preparation of 2-acylaminothiazole derivs. or salts thereof as C-mpl  
receptor ligands for proliferating human C-mpl-Ba/F3 cells and  
increasing platelets via promoting the formation of megakaryocytic  
colony)  
RN 570404-70-5 HCAPUIS  
CN Acetic acid, 2-(chloro-4-[[5-(4-cyclohexyl-1-piperazinyl)-4-(4-  
fluorophenyl)-2-thiazolyl]amino]carbonyl]phenoxy)-, hydrochloride (SCI)  
(CA INDEX NAME)

L4 ANSWER 19 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN  
ED Entered STN: 06 Dec 2002  
GI



II


AB The title compds. [I: X1 = O, S; R1, R2 = H, alkyl; or R1 and R2 may together with the carbon atom to which they are bonded form a 3-5 membered heterocyclic ring; R3 = H, halo, Me, OMe; R5 = H, alkyl; R2 = NH, NMe, or one of Y and Z is N, and the other is O or S; R6 = (un)substituted Ph or pyridyl (wherein the N is in position 2 or 3), with the provision that when R6 is pyridyl, the N is unsubstituted], were prepared E.g., a multi-step synthesis of the acid II which showed EC50 of 5 nM against hPPAR $\alpha$  binding, was given.

ACCESSION NUMBER: 2002:927419 HCAPLUS  
DOCUMENT NUMBER: 138:14053  
TITLE: Preparation of oxazoles and thiazoles as activators of the hPPAR $\alpha$  receptor  
INVENTOR(S): Gellibert, Francoise Jeanne  
PATENT ASSIGNEE(S): Glaxo Group Limited UK  
SOURCE: PCT Int. Appl., 33 pp.  
CODEN: P1XXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096895	A1	20021205	WO 2002-EP5886	20020529
W:	AE, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, NZ, OS, PT, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, ZA, ZM, ZW			
	GH, GM, KE, LS, MW, NZ, SD, SL, SZ, TG, UG, ZM, AT, BE, CH, CY, DE, DK, FI, FR, GB, GR, HU, ID, IL, IN, JP, KR, KZ, LK, LR, LY, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, NZ, OS, PT, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, ZA, ZM, ZW			
	CA 2448205	AA	20021205	CA 2002-2448205
	EP 1399430	A1	20040324	EP 20020529
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			


L4 ANSWER 19 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 IE, SI, LT, LV, FI, RO, MX, CY, AL, TR  
 BR 2002009785 A 20040601 BR 2002-9785 20020529  
 JP 2004532267 T2 20041021 JP 2003-500074 20020529  
 CN 1633421 A 20050629 CN 2002-814942 20020529  
 NZ 529754 A 20051223 NZ 2002-529754 20020529  
 ZA 2003009095 A 20050221 ZA 2003-9095 20031121  
 US 2005070517 A1 20050331 US 2004-478936 20040510  
 PRIORITY APPLN. INFO.: GB 2001-13231 A 20010531  
 WO 2002-EP5886 W 20020529

OTHER SOURCE(S): MARPAT 138:14053  
 IT 477740-73-1P  
 RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of thiazoles or oxazoles for the treatment of hPPAR $\alpha$  mediated diseases)  
 RN 477740-73-1 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-5-[4-(trifluoromethyl)phenyl]-2-thiazolyl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




IT 477740-60-6P 477740-62-8P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of thiazoles or oxazoles for the treatment of hPPAR $\alpha$  mediated diseases)  
 RN 477740-60-6 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[5-(4-ethylphenyl)-4-methyl-2-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 477740-62-8 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[5-(4-fluorophenyl)-4-methyl-2-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




IT 477740-61-7P 477740-63-9P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of thiazoles or oxazoles for the treatment of hPPAR $\alpha$  mediated diseases)  
 RN 477740-61-7 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[5-(4-ethylphenyl)-4-methyl-2-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 477740-63-9 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[5-(4-fluorophenyl)-4-methyl-2-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



IT 477740-72-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of thiazoles or oxazoles for the treatment of hPPAR $\alpha$  mediated diseases)  
 RN 477740-72-0 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-5-[4-(trifluoromethyl)phenyl]-2-thiazolyl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10518347

L4 ANSWER 20 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 06 Dec 2002  
 GI



AB The title compds. (I; R1, R2 = H, alkyl; or R1 and R2 may together with the carbon atom to which they are bonded form a 3-5 membered cycloalkyl ring; X1 = O, S; R3, R4, R8 and R9 = H, halo, Me, OMe; R5 = H, alkyl; or R4 and R5 together form a 3-6 membered cycloalkyl ring; X2 = NH, NMe, O; one of Y and Z is N, and the other is O or S; R6 = (un)substituted Ph, pyridyl (wherein the N is in position 2 or 3), with the provision that when R6 is pyridyl, the N is unsubstituted; R7 = alkyl, alkylheteroaryl, alkylphenyl, etc., with the proviso that when R1 and R2 are Me, R8 and R9 are H, R5 is H, then R7 cannot be Me or CF3) and their esters, were prepared. E.g., a multi-step synthesis of the acid II which showed EC50 of 1.7 nM in hPPARα assay, was given.


ACCESSION NUMBER: 2002:927418 HCAPLUS  
 DOCUMENT NUMBER: 138:14052  
 TITLE: Preparation of thiazoles or oxazoles as selective hPPARα agonists for treatment of cardiovascular and related diseases  
 INVENTOR(S): Dumaitre, Bernard Andre; Gosmini, Romain Luc Marie  
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK  
 SOURCE: PCT Int. Appl., 35 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096894	A1	20021205	WO 2002-EP5885	20020529

L4 ANSWER 20 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 IT 477771-89-4P 477771-93-0P 477771-95-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (Preparation of thiazoles or oxazoles for the treatment of hPPARα mediated diseases)

RN 477771-89-4 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[4-methyl-2-[[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]ethyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A

RN 477771-93-0 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[4-(phenoxyethyl)-2-[[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]ethyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2448103 AA 20021205 CA 2002-2448103 20020529  
 NZ 529718 A 20031219 NZ 2002-529718 20020529  
 EP 1392665 A1 20040303 EP 2002-738123 20020529  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 BR 2002010077 A 20040622 BR 2002-10077 20020529  
 CN 1529698 A 20040915 CN 2002-811080 20020529  
 JP 2004532266 T2 20041021 JP 2003-500073 20020529  
 ZA 2003008864 A 20050214 ZA 2003-8864 20031113  
 NO 2003005316 A 20031128 NO 2003-5316 20031128  
 US 2004176427 A1 20040909 US 2004-478259 20040429  
 US 6867225 B2 20050315

PRIORITY APPLN. INFO.:


OTHER SOURCE(S): MARPAT 138:14052

IT 343321-96-0P

RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (Preparation of thiazoles or oxazoles for the treatment of hPPARα mediated diseases)


RN 343321-96-0 HCAPLUS

CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-[[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 477771-95-2 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[4-(2-thienylmethyl)-2-[[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]ethyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A








IT 477771-90-7P 477771-94-1P 477771-96-3P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of thiazoles or oxazoles for the treatment of hPPARα  
 mediated diseases)  
 RN 477771-90-7 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[4-methyl-2-[4-  
 (trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]ethyl]phenoxy]- (9CI)  
 (CA INDEX NAME)




RN 477771-94-1 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[4-(phenoxy)methyl]-2-[4-  
 (trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]- (9CI)  
 (CA INDEX NAME)

L4 ANSWER 20 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 mediated diseases)


RN 343321-95-9 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-  
 thiazolyl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX  
 NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT




RN 477771-96-3 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[4-(2-thienylmethyl)-2-[4-  
 (trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]- (9CI)  
 (CA INDEX NAME)



IT 343321-95-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of thiazoles or oxazoles for the treatment of hPPARα)

L4 ANSWER 21 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 06 Dec 2002  
 GI




AB A method of preparing thiazole derivative (I), and pharmaceutically  
 acceptable  
 salts and solvates thereof are described. Polymorphs of this compound and  
 their use as peroxisome proliferator-activated receptor (PPAR) ligands are  
 also disclosed. Thus, Form 2 of I was dissolved in EtOAc and treated with  
 isoctane allowing the compound to crystallize.

ACCESSION NUMBER: 2002:927417 HCAPLUS  
 DOCUMENT NUMBER: 138:16612  
 TITLE: Preparation of polymorphs of a thiazole peroxisome  
 proliferator-activated receptor-ligand  
 INVENTOR(S): Boyer, Thierry; Day, Caroline Jane; Whitehead, Andrew  
 Jonathan  
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK  
 SOURCE: PCT Int. Appl., 30 pp.  
 CODEN: PIXX02  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096893	A1	20021205	WO 2002-EP5884	20020529
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HL, HR, NE, SN, TD, TG			
CA 2448101	AA	20021205	CA 2002-2448101	20020529
EP 1395572	A1	20040310	EP 2002-747330	20020529
EP 1395572	B1	20060111		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002009892	A	20040608	BR 2002-9892	20020529
JP 2004532265	T2	20041021	JP 2003-500072	20020529
CN 1551871	A	20041201	CN 2002-810885	20020529
NZ 529486	A	20051223	NZ 2002-529486	20020529
AT 315556	E	20060215	AT 2002-747330	20020529
ZA 2003008570	A	20050203	ZA 2003-8570	20031103
NO 2003005313	A	20031209	NO 2003-5313	20031128
US 2004242657	A1	20041202	US 2004-478260	20040427
PRIORITY APPLN. INFO.:			GB 2001-13232	A 20010531


10518347

L4 ANSWER 21 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 WO 2002-EP5884 W 20020529  
 IT 343321-96-0P  
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of polymorphs of thiazole derivative as peroxisome  
 proliferator-activated receptor-ligand)  
 RN 343321-96-0 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-  
 thiazolyl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 22 Nov 2002  
 GI



AB The title compds. (I; X1 = O, S, NH, NMe, alkyl; R1, R2 = H, alkyl; R3-R5 = H, Me, OMe, CF3, halo; m = 0-3; X2 = (CR1OR11)n, O, S, OCH2; n = 1-2; R6, R7, R10, R11 = H, F, alkyl, etc.; one of Y and Z = CH, the other = S, O with the proviso that Y cannot be substituted and Z can only be substituted when it is carbon; R8 = (un)substituted Ph, pyridyl (wherein the N is in position 2 or 3) with the provision that when R3 = pyridyl, the N is unsubstituted; R9 = alkyl, CF3, CH2D (D = N-substituted piperazino, furyl, piperidino, etc.); R26, R27 = H, alkyl or R26 and R27, together with the carbon atom to which they are bonded form a 3-5 membered cycloalkyl ring) and their pharmaceutically acceptable salts, useful for the treatment of a hPPAR mediated disease or condition such as dyslipidemia, syndrome X, heart failure, hypercholesterolemia, cardiovascular disease, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia, inflammation and anorexia nervosa, were prepared Thus, coupling (5-[4-(trifluoromethyl)phenyl]-3-furyl)methanol with Et (4-mercapto-2-methylphenoxy)acetate followed by hydrolysis of the resulting ester afforded the acid II.


ACCESSION NUMBER: 2002:888731 HCAPLUS  
 DOCUMENT NUMBER: 137:384743  
 TITLE: Preparation of furan and thiophene derivatives that activate human peroxisome proliferator activated receptors  
 INVENTOR(S): Beswick, Paul John; Hamlett, Christopher Charles  
 Frederick, Patel, Vipulkumar; Sierra, Michael  
 Lawrence, Ramsden, Nigel Graham  
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK  
 SOURCE: PCT Int. Appl., 141 pp.  
 CODEN: PIXXD2

L4 ANSWER 22 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092590	A1	20021121	WO 2002-GB2152	20020509
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2446797	AA	20021121	CA 2002-2446797	20020509
EP 1392674	A1	20040303	EP 2002-722506	20020509
EP 1392674	B1	20050810		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
CN 1507442	A	20040623	CN 2002-809694	20020509
BR 2002009468	A	20040803	BR 2002-9468	20020509
JP 2004534035	T2	20041111	JP 2002-589475	20020509
AT 301649	E	20050815	AT 2002-722506	20020509
ZA 2003008352	A	20050127	ZA 2003-8352	20031027
NO 2003004986	A	20031110	NO 2003-4986	20031110
US 2004157890	A1	20040812	US 2004-476194	20040323
PRIORITY APPLN. INFO.:			GB 2001-11523	A 20010511
			WO 2002-GB2152	W 20020509

OTHER SOURCE(S): MARPAT 137:384743  
 IT 343322-43-0P  
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);  
 BIOL (Biological study); PREP (Preparation)  
 (preparation of furan and thiophene derivs. that activate human  
 peroxisome  
 proliferator activated receptors)  
 RN 343322-43-0 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]- (9CI)  
 (CA INDEX NAME)

L4 ANSWER 22 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 343322-42-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of furan and thiophene derivs. that activate human  
 peroxisome  
 proliferator activated receptors)  
 RN 343322-42-9 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-,  
 ethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A

L4 ANSWER 22 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 23 Aug 2002

AB A solved three-dimensional crystal structure of a human PPAR $\alpha$  ligand-binding domain polypeptide is disclosed, along with a crystal form of the PPAR $\alpha$  ligand-binding domain polypeptide. Methods of designing modulators of the biol. activity of PPAR $\alpha$  and other PPAR ligand binding domain polypeptides are also disclosed.

ACCESSION NUMBER: 2002:637711 HCAPLUS

DOCUMENT NUMBER: 137:181391

TITLE: Crystallization, crystal structure and drug design use of a human PPAR $\alpha$  ligand-binding domain  
Lambert, Millard Hurst III; Montana, Valerie Gail; Xu, Huaqiang Eric

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 286 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064632	A2	20020822	WO 2002-US3278	20020131
WO 2002064632	A3	20030814		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004137518	A1	20040715	US 2003-467048	20030801
PRIORITY APPLN. INFO.:			US 2001-265698P	P 20010201
			WO 2002-US3278	W 20020131


IT 343321-96-0P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(crystal structure of PPAR $\alpha$  ligand-binding domain complexes with ligand; crystallization, crystal structure and drug design use of human PPAR $\alpha$  ligand-binding domain)

RN 343321-96-0 HCAPLUS

CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 343321-95-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of PPAR $\alpha$  ligand; crystallization, crystal structure and

drug design use of human PPAR $\alpha$  ligand-binding domain)

RN 343321-95-9 HCAPLUS


CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 24 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 28 Jun 2002

GI



AB The title compds. [I: X = O, S; X1 = O, S; Y = S, O; R1, R2 = H, Me, halo; R4, R5 = H, alkyl; or R4 and R5 may, together with the carbon atom to which they are bonded, form a 3-5 membered cycloalkyl ring; R6, R7 = H, alkyl, allyl; R3 = halo, alkyl, CF3; y = 0-5] and pharmaceutically acceptable salts, solvates and hydrolyzable esters thereof which act as hPPAR $\alpha$  agonists, were prepared. Thus, reacting Et 2-hydroxyisobutyrate with the bromide II (preparation given) in the presence of NaH in THF (31%) followed by hydrolysis of the resulting ester (25%) afforded I [R1, R2 = H; R3 = 4-CF3; R4, R5 = Me; R6, R7 = H; X, X1 = O; Y = S; y = 1] which showed EC50 of 0.002  $\mu$ M in hPPAR $\alpha$  assay.

ACCESSION NUMBER: 2002:487540 HCAPLUS

DOCUMENT NUMBER: 137:47192

TITLE: Preparation of substituted oxazoles and thiazoles as hPPAR $\alpha$  agonists

INVENTOR(S): Sierra, Michael Lawrence

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002050047	A1	20020627	WO 2001-EP14886	20011218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				


L4 ANSWER 24 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG  
 AU 2002033271 A5 20020701 AU 2002-33271 20011218  
 EP 1345916 A1 20030924 EP 2001-984857 20011218  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 JP 2004517100 T2 20040610 JP 2002-551544 20011218  
 US 2004147571 A1 20040729 US 2003-451298 20031117  
 PRIORITY APPLN. INFO.: US 2000-257070P P 20001220  
 WO 2001-EP14886 W 20011218

OTHER SOURCE(S): MARPAT 137:47192  
 IT 343321-96-0P  
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);  
 BIOL (Biological study); PREP (Preparation)  
 (pos. control in assay; preparation of substituted oxazoles and  
 thiazoles as  
 hPPAR alpha agonists)  
 RN 343321-96-0 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-  
 thiazolyl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



IT 343321-95-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of substituted oxazoles and thiazoles as hPPAR alpha  
 agonists)  
 RN 343321-95-9 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-  
 thiazolyl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX  
 NAME)

L4 ANSWER 25 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 28 Jun 2002  
 GI



AB The invention includes low mol. weight, non-peptidic, non-peptidomimetic,  
 organic

mols. that can act as modulators of mammalian complement C5a receptors,  
 preferably ones that act as high affinity C5a receptor ligands and also  
 such ligands that can act as antagonists or inverse agonists of complement  
 C5a receptors. Preferred compds. of the invention possess some or all of  
 the following properties in that they are: (1) multi-aryl in structure;  
 (2) heteroaryl in structure; (3) a pharmaceutically acceptable oral dose  
 can provide a detectable in vivo effect; (4) comprise fewer than four or  
 preferably no amide bonds, and (5) capable of habiting leukocyte  
 chemotaxis at nanomolar or sub-nanomolar concns. Such compds. include  
 imidazoles I [R1 = H, OH, halo, etc.; R2 = alkyl, cycloalkyl, etc.; R3 H,  
 alkyl, etc.; R4 = alkyl, alkenyl, cycloalkyl, etc.; Ar1, Ar2 =  
 (un)substituted carbocyclic aryl, arylalkyl, etc.], pyrazoles II [R = H,  
 OH, halo, etc.; R2, R3 = H, OH, halo, etc.; R4 = alkyl, alkenyl,  
 cycloalkyl, etc.; Ar1, Ar2 = (un)substituted carbocyclic aryl, arylalkyl,  
 etc.], amides Ar1CONR2 [III: R1, R2 = alkyl, alkenyl, cycloalkyl, etc.;  
 Ar1 = (un)substituted carbocyclic aryl, arylalkyl, etc.], etc. Detailed  
 preparation of some compds. I-III was given. E.g., a multi-step synthesis

of I  
 [Ar1 = Ph; R1, R3 = H; R2 = Bu; R4, Ar2 = 3,4-methylenedioxyphenyl] was  
 presented. The invention also includes pharmaceutical composition


comprising  
 such compds. I-III and the use of such compds. in treating a variety of  
 inflammatory and immune system disorders.

ACCESSION NUMBER: 2002:487497 HCAPLUS  
 DOCUMENT NUMBER: 137:78952  
 TITLE: Preparation of substituted imidazoles, pyrazoles and  
 amides as high affinity C5a receptor modulators  
 INVENTOR(S): Thuckauf, Andrew; Zhang, Xiaoyan; He, Xia-Shu; Zhao,  
 He; Peterson, John; Maynard, George; Ohliger, Robert  
 PATENT ASSIGNEE(S): Neurogen Corporation, USA  
 SOURCE: PCT Int. Appl., 609 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002049993	A2	20020627	WO 2000-US26816	20000929
WO 2002049993	A3	20030220		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,  
 CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,


L4 ANSWER 24 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 25 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,  
 SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,  
 ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CO, CR, CU, CY, DE, DK, ES,  
 FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
 CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG  
 CA 2420215 AA 20020627 CA 2000-2420215 20000929  
 AU 2000076225 A5 20020701 AU 2000-76225 20000929  
 EP 1322309 A2 20030702 EP 2000-965522 20000929  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL  
 ZA 2003001160 A 20040212 ZA 2003-1160 20000929  
 BR 2000017338 A 20040427 BR 2000-17338 20000929  
 JP 2004525873 T2 20040826 JP 2002-551496 20000929  
 NO 2003001370 A 20030530 NO 2003-1370 20030326  
 PRIORITY APPLN. INFO.: US 2000-227454P P 20000823  
 WO 2000-US26816 W 20000929

OTHER SOURCE(S): MARPAT 137:78952  
 IT 439571-14-9P 439571-15-0P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of substituted imidazoles, pyrazoles and amides as high  
 affinity C5a receptor modulators)  
 RN 439571-14-9 HCAPLUS  
 CN Acetic acid, [4-[[[1-butyl-2,4-diphenyl-1H-imidazol-5-yl]methyl]  
 (phenyl)methyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 439571-15-0 HCAPLUS  
 CN Acetic acid, [4-[[[1-butyl-2,4-diphenyl-1H-imidazol-5-yl]methyl]  
 (cyclohexylmethyl)amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



10518347

L4 ANSWER 26 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 22 Feb 2002  
 GI



AB The title compds. I [R1 and R2 are each hydrogen, C1-8 alkyl, an aryl or heterocyclic group which may be substituted, or the like; A is oxygen, sulfur, or the like; X1 and X2 are each O, S(O)p (wherein p is an integer of 0 to 2), or the like; Y is optionally substituted C1-8 alkylene; Z is O or S; R3 and R4 are each optionally substituted C1-8 alkyl; and R8 is hydrogen or C1-8 alkyl; a proviso is given] are prepared. The PPAR  $\delta$  activating activity of 2-[4-{3-[2-(2,4-dichlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]phenoxy]-2-methylpropionic acid (II) is more potent than that shown by the known L-165041; II also showed high selectivity for the PPAR  $\delta$  receptors.

ACCESSION NUMBER: 2002:142686 HCAPLUS

DOCUMENT NUMBER: 136:200192

TITLE: Preparation of heterocyclic compounds as PPAR (peroxisome proliferator activated receptor)  $\delta$  activators

INVENTOR(S): Sakuma, Shogo; Endo, Tsuyoshi; Tendo, Atsushi; Takahashi, Toshihiro; Yoshida, Shinichi; Kobayashi, Kunio; Mochiduki, Nobutaka; Yamakawa, Tomio; Kanda, Takashi; Masui, Seichiro

PATENT ASSIGNEE(S): Nippon Chemphar Co., Ltd., Japan

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014291	A1	20020221	WO 2001-JP6836	20010809
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001077723	A5	20020225	AU 2001-77723	20010809
EP 1310494	A1	20030514	EP 2001-955606	20010809

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 08 Jun 2001  
 GI



AB The title compds. [I; X1 = O, S; R1, R2 = H, halo, Me, OMe; n = 1-2; X2 = NH, NMe, O; one of Y and Z = N, and the other = O, S; R3 = (un)substituted Ph, pyridyl (wherein the N is in position 2 or 3) with the provision that when R3 = pyridyl, the N is in position 2 or 3] and their pharmaceutically acceptable salts, useful as a selective hPPAR  $\alpha$  agonists, were prepared. E.g., a multi-step synthesis of the ester II was given. Biol. data for compds. I were presented.

ACCESSION NUMBER: 2001:416920 HCAPLUS

DOCUMENT NUMBER: 135:19630

TITLE: Preparation of substituted oxazoles and thiazoles as hPPAR  $\alpha$  activators

INVENTOR(S): Sierra, Michael Lawrence

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 77 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001040207	A1	20010607	WO 2000-EP11995	20001130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TW 555753	B	20031001	TW 2000-89125344	20001129
CA 2393190	AA	20010607	CA 2000-2393190	20001130
BR 2000016067	A	20020806	BR 2000-16067	20001130

L4 ANSWER 26 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 US 2004057739 A1 20040520 US 2003-344496 20030211  
 US 6787552 B2 20040907  
 PRIORITY APPLN. INFO.: JP 2000-243596 A 20000811  
 JP 2000-402893 A 20001228  
 WO 2001-JP6836 W 20010809

OTHER SOURCE(S): MARPAT 136:200192


IT 400760-22-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as PPAR  $\delta$  activators)

RN 400760-22-7 HCAPLUS

CN Propanoic acid, 2-[4-[[[2-(2-chlorophenyl)-5-(1-methylethyl)-4-oxazolyl]methyl]amino]carbonyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 TR 200201473 T2 20020923 TR 2002-1473 20001130  
 EP 1244642 A1 20021002 EP 2000-983189 20001130  
 EP 1244642 B1 20040428  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 AU 758758 B2 20030327 AU 2001-20030 20001130  
 JP 20030515597 T2 20030507 JP 2001-541891 20001130  
 AT 265442 E 20040515 AT 2000-983189 20001130  
 PT 1244642 T 20040930 PT 2000-983189 20001130  
 ES 2219423 T3 20041201 ES 2000-983189 20001130  
 NO 200202467 A 20020726 NO 2002-2467 20020524  
 US 6518290 B1 20030211 US 2002-148765 20020531  
 ZA 2002004241 A 20030702 ZA 2002-4241 20020728  
 HK 1047435 A1 20041126 HK 2002-109084 20021214  
 PRIORITY APPLN. INFO.: GB 1999-28561 A 19991202  
 GB 2000-3500 A 20000215  
 WO 2000-EP11995 W 20001130

OTHER SOURCE(S): MARPAT 135:19630

IT 343321-95-9P 343321-96-OP 343321-97-1P

343322-04-3P 343322-06-5P 343322-08-7P

343322-10-1P 343322-12-3P 343322-14-5P

343322-16-7P 343322-18-9P 343322-20-3P

343322-22-5P 343322-24-7P 343322-26-9P

343322-28-1P 343322-30-5P 343322-32-7P

343322-34-9P 343322-36-1P 343322-40-7P

343322-42-9P 343322-44-1P 343322-46-3P


343322-48-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of substituted oxazoles and thiazoles as hPPAR  $\alpha$  activators)

RN 343321-95-9 HCAPLUS

CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




10518347

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 343321-96-0 HCAPLUS

CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 343321-97-1 HCAPLUS

CN Propanoic acid, 2-methyl-2-[4-[[methyl[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 343322-04-3 HCAPLUS

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
thiazolyl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

RN 343322-10-1 HCAPLUS

CN Propanoic acid, 2-[4-[[[2-(4-aminophenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 343322-12-3 HCAPLUS

CN Propanoic acid, 2-[4-[[[2-(3,4-dichlorophenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Propanoic acid, 2-[4-[[[2-[4-(1,1-dimethylethyl)phenyl]-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 343322-06-5 HCAPLUS


CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-[4-(1-methylethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 343322-08-7 HCAPLUS


CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-(4-nitrophenyl)-5-

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 343322-14-5 HCAPLUS


CN Propanoic acid, 2-[4-[[[2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 343322-16-7 HCAPLUS

CN Propanoic acid, 2-[4-[[[2-(4-bromophenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 343322-18-9 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[2-(4-ethylphenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 343322-20-3 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[2-(4-ethylphenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 343322-26-9 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[2-(4-(trifluoromethoxy)phenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 343322-28-1 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[2-(4-methoxyphenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 343322-22-5 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[2-(4-fluorophenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 343322-24-7 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[2-(4-chlorophenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 343322-30-5 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[2-(4-ethynylphenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 343322-32-7 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[2-(4-(trifluoromethyl)phenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

10518347

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 343322-34-9 HCAPLUS  
CN Propanoic acid, 2-[[4-[[[2-(4-(1,1-dimethylethyl)phenyl]-4-(trifluoromethyl)-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 343322-36-1 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[[[4-[[[2-(4-(1,1-dimethylethyl)phenyl]-4-(trifluoromethyl)-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 343322-42-9 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[[[4-[[[2-(4-(1,1-dimethylethyl)phenyl]-4-(trifluoromethyl)-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 343322-44-1 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[[[4-[[[2-(4-(1,1-dimethylethyl)phenyl]-4-(trifluoromethyl)-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 343322-40-7 HCAPLUS  
CN Propanoic acid, 2-[[2-methoxy-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A



RN 343322-46-3 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[[[4-[[[2-(4-(1,1-dimethylethyl)phenyl]-4-(trifluoromethyl)-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 343322-48-5 HCAPLUS  
CN Propanoic acid, 2-methyl-2-[[[4-[[[2-(4-(1,1-dimethylethyl)phenyl]-4-(trifluoromethyl)-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)




10518347

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 343321-98-2P 343321-99-3P 343322-00-9P  
 343322-05-4P 343322-07-6P 343322-09-8P  
 343322-11-2P 343322-13-4P 343322-15-6P  
 343322-17-8P 343322-19-0P 343322-21-4P  
 343322-23-6P 343322-25-8P 343322-27-0P  
 343322-29-2P 343322-31-6P 343322-33-8P  
 343322-35-0P 343322-37-2P 343322-41-8P  
 343322-43-0P 343322-45-2P 343322-47-4P  
 343322-49-6P 343322-50-9P 343322-51-0P  
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of substituted oxazoles and thiazoles as hPPAR alpha activators)  
 RN 343321-98-2 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 343321-99-3 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-, compd. with

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2  
 CRN 6284-40-8  
 CMF C7 H17 N O5


Absolute stereochemistry.



RN 343322-05-4 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-[4-(1,1-dimethylethyl)phenyl]-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1  
 CRN 343321-96-0  
 CMF C23 H21 F3 N2 O4 S




CM 2  
 CRN 111-42-2  
 CMF C4 H11 N O2

HO-CH<sub>2</sub>-CH<sub>2</sub>-NH-CH<sub>2</sub>-CH<sub>2</sub>-OH


RN 343322-00-9 HCAPLUS  
 CN D-Glucitol, 1-deoxy-1-(methylamino)-, 2-methyl-2-[4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]propanoate (salt) (9CI) (CA INDEX NAME)

CM 1  
 CRN 343321-96-0  
 CMF C23 H21 F3 N2 O4 S

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 343322-07-6 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-[4-(1-methylethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 343322-09-8 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-[4-(nitrophenyl)-5-thiazolyl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

10518347

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 343322-11-2 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(4-aminophenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 343322-13-4 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3,4-dichlorophenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 343322-19-0 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(4-ethylphenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 343322-21-4 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[2-(4-methyl-2-phenyl-5-thiazolyl)carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 343322-15-6 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(3-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 343322-17-8 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(4-bromophenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 343322-23-6 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(4-fluorophenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 343322-25-8 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-(4-chlorophenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

10518347

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 343322-27-0 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-(4-(trifluoromethoxy)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 343322-29-2 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[2-(4-methoxyphenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 343322-35-0 HCAPLUS  
 CN Propanoic acid, 2-[4-[[[2-[4-(1,1-dimethylethyl)phenyl]-4-(trifluoromethyl)-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 343322-37-2 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[4-methyl-2-(4-(trifluoromethyl)phenyl)-5-oxazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 343322-31-6 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[2-(4-ethynylphenyl)-4-methyl-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 343322-33-8 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[4-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 343322-41-8 HCAPLUS  
 CN Propanoic acid, 2-[2-methoxy-4-[[[4-methyl-2-(4-(trifluoromethyl)phenyl)-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)




RN 343322-43-0 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[4-methyl-2-(4-(trifluoromethyl)phenyl)-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

10518347

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 343322-45-2 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[4-methyl-2-{4-[(1-methylethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 343322-47-4 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[5-methyl-2-{4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 thiazolyl]carbonyl]amino]methyl]phenoxy]-, compd. with 2-aminoethanol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 343321-96-0  
 CMF C23 H21 F3 N2 O4 S




CM 2

CRN 141-43-5  
 CMF C2 H7 N O


H<sub>2</sub>N-CH<sub>2</sub>-CH<sub>2</sub>-OH

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 343322-49-6 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[5-methyl-2-{3-(trifluoromethyl)phenyl]-4-thiazolyl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 343322-50-9 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[5-methyl-2-{4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-, monosodium salt (9CI) (CA INDEX NAME)



RN 343322-51-0 HCAPLUS  
 CN Propanoic acid, 2-methyl-2-[4-[[[5-methyl-2-{4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-, monosodium salt (9CI) (CA INDEX NAME)


L4 ANSWER 28 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 19 Jan 2001  
 GI



AB Novel classes of heterocyclic compds., e.g., I (X = CH, Y = N, R = Ph, cyclopentyl, 3-ClC<sub>6</sub>H<sub>4</sub>, etc.; X = N, Y = CH, R = 4-ClC<sub>6</sub>H<sub>4</sub>, Ph, 3-Me-4-MeOC<sub>6</sub>H<sub>3</sub>, etc.), as adenosine antagonists were developed based on a template approach. Structure-affinity relationships revealed insights for extended knowledge of the receptor-ligand interaction. The authors replaced the bicyclic heterocyclic ring system of earlier described isoquinoline and quinazoline adenosine A<sub>3</sub> receptor ligands by several monocyclic rings and investigated the influence thereof on adenosine receptor affinity. The thiazole or thiadiazole derivs. seemed most promising, so the authors continued their investigations with these two classes of compds. The large difference between a pyridine and isoquinoline ring in binding adenosine A<sub>1</sub> and A<sub>3</sub> receptors showed the importance of the second ring of the isoquinoline ligands. The authors prepared several N-[4-(2-pyridyl)thiazol-2-yl]benzamides, and these compds. showed adenosine affinities in the micromolar range. Most surprising in the series of the N-[4-(2-pyridyl)thiazol-2-yl]amides were the retained adenosine affinities by introduction of a cyclopentanamide instead of the benzamide. A second series of compds., the thiadiazolobenzamide series of compds., revealed potent and selective adenosine receptor antagonists, especially N-(3-phenyl-1,2,4-thiadiazol-5-yl)-4-hydroxybenzamide I (LUF5437, II) (X = N; R = 4-HOC<sub>6</sub>H<sub>4</sub>) showing a K<sub>i</sub> value of 7 nM at the adenosine A<sub>1</sub> receptor and N-(3-phenyl-1,2,4-thiadiazol-5-yl)-4-methoxybenzamide I (LUF5417, III) (X = N; R = 4-MeOC<sub>6</sub>H<sub>4</sub>) with a K<sub>i</sub> value of 82 nM at the adenosine A<sub>3</sub> receptor. 4-Hydroxybenzamide II is the most potent adenosine A<sub>1</sub> receptor antagonist of this new class of compds. Structure-affinity relationships showed the existence of a steric restriction at the para-position of the benzamide ring for binding adenosine A<sub>1</sub> and A<sub>3</sub> receptors. The electronic nature of the 4-substituents played an important role in binding the adenosine A<sub>3</sub> receptor. Cis- and trans-4-substituted cyclohexyl derivs. were made next to the 4-substituted benzamide analogs. The authors used them to study the proposed specific interaction between the adenosine A<sub>1</sub> receptor and the 4-hydroxy group of this class of thiadiazole compds., as well as a suggested special role for the 4-methoxy group in binding the A<sub>3</sub> receptor. Both the adenosine A<sub>1</sub> and A<sub>3</sub> receptor slightly preferred the trans-analogs over the cis-analogs, while all compds. showed low affinities at the adenosine A<sub>2A</sub> receptor. The investigations provided the potent and highly selective adenosine A<sub>1</sub> antagonist N-(3-phenyl-1,2,4-thiadiazol-5-yl)-trans-4-hydroxycyclohexanamide (VUF5472) showing a K<sub>i</sub> value of 20 nM. A third series of compds. was formed by urea analogs, N-substituted with thiazole and thiadiazole heterocycles. The SAR of this class of compds. was not commensurate with the SAR of the previously described quinazoline urea. On the basis of these findings the authors suggest the existence of a special interaction between adenosine receptors and a region of high electron d. positioned between the thia(dia)zole ring and phenyl(pyridyl) ring. Mol. electrostatic potential contour plots showed that for this

10518347

L4 ANSWER 28 OF 28 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
reason the ligands need either a thiadiazole ring instead of a thiazole or  
a 2-pyridyl group instead of a Ph. The derived novel classes of  
antagonists will be useful for a better understanding of the mol.  
recognition at the adenosine receptors.  
ACCESSION NUMBER: 2001:44770 HCAPLUS  
DOCUMENT NUMBER: 134:252299  
TITLE: Thiazole and thiadiazole analogs as a novel class of  
adenosine receptor antagonists  
AUTHOR(S): van Muijlwijk-Koezen, Jacqueline E.; Timmerman,  
Hendrik; Vollinga, Roeland C.; von Kuenzel, Jacobien  
Frijtag, de Groote, Miriam; Visser, Sven; IJzerman,  
Adriaan P.  
CORPORATE SOURCE: Department of Pharmacochimistry Division of Medicinal  
Chemistry Leiden/Amsterdam Center for Drug Research,  
Vrije Universiteit, Amsterdam, 1081 HV, Neth.  
SOURCE: Journal of Medicinal Chemistry (2001), 44(5), 749-762  
CODEN: JMCMAR; ISSN: 0022-2623  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 331472-35-6P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); SPN (Synthetic preparation); BIOL (Biological  
study); PREP (Preparation)  
(preparation, adenosine antagonist activity, and structure-activity  
relationship of thiazole and thiadiazole analogs)  
RN 331472-35-6 HCAPLUS  
CN Acetic acid, [4-[[[3-phenyl-1,2,4-thiadiazol-5-yl]amino]carbonyl]phenoxy]-  
(9CI) (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10518347

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

148.14

315.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-21.00

-21.00

STN INTERNATIONAL LOGOFF AT 13:38:32 ON 08 JUL 2006